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73 Introduction
Inflammation, as a biological phenomenon, is associated with tissue remodeling. The
amount of reshaping work varies from individual leukocytes passing through tissue
barriers, via wound healing and matrix rebuilding to irreparable tissue destruction.
The ideas of tissue destruction and modeling were apparent in the middle of 20th
century, and the developement of biological methodology allowed much of the detailed
research on the role of matrix metalloproteinases and other key peptidases in connective
tissue turnover. Further research revealed the regulation of these effectors and their genes
by inflammatory cytokine signals.
This study is a globally modest but personally invaluable exercise that focuses on two
aspects of inflammation: first, the final effectors of tissue remodeling and degradation –
matrix metalloproteinases and second, the effect of a common drug family, statins,  on the
measurable indices of inflammatory tissue destruction in the mouth.
This thesis consists of four original studies, here referred to by roman numerals as
study I to study IV.
First, in study I, we started from investigating and measuring matrix
metalloproteinase-8 and matrix metalloproteinase-9 in patients being treated for
rheumatoid arthritis. The idea of the study was to isolate the cells from the inflamed joint
and compare them to those isolated from the peripheral blood of the same patient.
Second, we continued the study of arthritides, and were able to show that MMP-13 is
present in the inflamed joint in rheumatoid arthritis. During the study, we could unite
experts in orthopedic surgery, rheumatology and molecular biology to show the presence
of this enzyme directly in diseased human joint tissue.
Third, we concentrated on living patients with rheumatoid arthritis. It had been
suggested that tetracyclines may have an inhibitory action on matrix metalloproteinases.
Since these enzymes were considered to be effectors of tissue destruction involved in
rheumatoid arthritis, we wanted to examine whether treatment with a tetracycline would
have a measurable effect in our patients. To evaluate the state of joint inflammation we
used both biochemical, immunological and clinical psychometric tools of patient
disability.
Fourth, we wanted to change our approach to inflammation and study measurable
inflammatory tissue loss in periodontitis patients. Statins had been shown to inhibit protein
isoprenylation. This isoprenyl modification had been shown to be important in the
localization and activation of several intracellular mediators of inflammatory signal
transduction. Our hypothesis was that because the statins had been shown to have an anti-
inflammatory effect, they could have a measurable effect in periodontal inflammation.
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4.1 Inflammation in arthritides
4.1.1. Inflammation in rheumatoid arthritis
Rheumatoid arthritis is a chronic polyarthritis involving symmetrical inflammation of
joints of hand and feet (Arnett et al., 1988; Firestein 2003, Table 1). It is caused by the
interplay of a possible triggering infectious agent, initiation of immune response and
perpetuation of local immune response in genetically susceptible individuals (Firestein &
Corr 2005). Inflammation of rheumatoid arthritis involves thickening and villous
hyperplasia of the synovial lining, which is often covered by a fibrin-like layer, leukocyte
effusion of the synovial fluid, subsynovial infiltrates of lymphocytes, focal necrotic
synovial tissue changes and proliferation and invasion of the synovial pannus to the joint
cartilage (Fox 2005). The subsynovial lymphocyte foci secrete proinflammatory cytokines
and produce immunoglobulins. In rheumatoid arthritis, the T-lymphocyte response is of
Th1 type rather than Th2 type, leading to perpetuation of the inflammation (Smith &
Haynes 2004; Skapenko et al., 2005).
Neutrophils are short-lived cells with a life span outside the vascular compartment of
approximately 1-2 days. Their turnover in inflammatory synovial fluid is quite extensive.
If there is 50 ml synovial fluid in the knee joint, containing 80 x 109/l leukocytes (often
>90% of which are neutrophils), it means that almost 2 x 109 neutrophils undergo
apoptosis on a daily basis in synovial fluid. As all these neutrophils represent packages of
preformed enzymes, they together form a significant source of neutrophil enzymes,
including elastase, and cathepsin G. It may also be that the significant thickening and
villous hyperplasia of the lining is in part related to its function in the handling of
apoptotic and necrotic neutrophil cell rests originating from the synovial fluid filled joint
cavity.
Table 1 Diagnostic Criteria for rheumatoid arthritis (Arnett et al., 1988)
Criterion
1. Morning stiffness
2. Arthritis of three or more joint areas
3. Arthritis of hand joints
4. Symmetric arthritis
5. Rheumatoid nodules
6. Serum rheumatoid factor
7. Radiographic changes
9The perpetuation of the inflammation may involve local cytokine networks between
fibroblast-like synoviocytes and macrophagelike synoviocytes in the intimal lining. It has
also been suggested that perpetuation of arthritis may relate to some immunogenic
antigenic structures produced from the avascular hyaline articular cartilage (Dodge &
Poole, 1989; Warnock & Goodacre 1997; Janeway et al., 2001). Therefore, proteinases
may play a dual role in arthritis by mediating tissue destruction and producing potentially
antigenic tissue degradation products.
These paracrine and autocrine cytokine and proteinase networks can produce factors that
maintain active inflammation by activating cells in the local environs, leading to
expression of other cytokines, matrix metalloproteinases, and small molecule mediators in
adjacent cells (Firestein 2003; Sweeney & Firestein 2003; Müller-Ladner et al., 2005).
Ultimately, untreated rheumatoid arthritis leads to tissue destruction in the involved joints
and permanent disability (Fox 2005).
Some authors divide the development of rheumatoid arthritis to pre-rheumatoid stages and
stages after joint involvement (Figure 1). An alternative view is that joint tissues are
affected at a stage preceding establishment arthritis. In addition, circulating leukocytes
have been proposed to be in an activated state in patients with rheumatoid arthritis.
Figure 1 Pathogenesis of rheumatoid arthritis. (Austen et al., 2001).
Key effectors in the tissue destruction of rheumatoid arthritis are matrix
metalloproteinases (Sweeney & Firestein 2003) secreted in response to the
proinflammatory stimulation of tumor necrosis factor alpha and interleukin-1β (Dayer,
2002).
In addition to destroying joint structures and leading to disability, the chronic
inflammation of rheumatoid arthritis causes a systemic burden on the cardiovascular
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system and leads to premature development of cardiovascular disease (Myllykangas-
Luosujärvi et al., 1995; Abou-Raya & Abou-Raya 2006; Gonzales-Gay et al., 2005; Giles
et al., 2005; Snow & Mikuls 2005; Yeh 2004).
4.1.2. Indices of pain and disability
ACR Functional classification
American College of Rheumatology revised criteria for classification of global functional
status in rheumatoid arthritis. The ACR revised criteria (Hochberg et al., 1991, Table 2)
classify patient in classes I and IV according to functional capacity. This classification can
be considere fairly simple and straightforward. The revision of the functional classification
was reworked on, because the preceding criteria had limitations in definition and
guidelines for application, and the clustering phenomenon of patients into functional class
II. After this revision, the distribution of subjects with rheumatoid arthritis in the four
classes was symmetric (Hochberg et al., 1988).
Table 2 ACR revised criteria for functional classification of status in subjects with
rheumatoid arthritis * (Hochberg et al., 1988).
Class I Completely able to perform usual activities of daily living
(self-care, vocational, and avocational)
Class II Able to perform usual self-care and vocational activities,
but limited in avocational activities
Class III Able to perform usual self-care activities, but limited in
vocational and avocational activities
Class IV Limited in ability to perform usual self-care, vocational,
and avocational activities
* Usual self-care activities include dressing, feeding, bathing, grooming and toileting.
Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities are
patient-desired and age- and sex-specific.
Rithcie Joint Score Index (JSI) (Ritchie et al., 1968)
Physicians need methods to estimate the activity of diseases, and this is escpecially true
with chronic disabling conditions like rheumatoid arthritis. Ritchie et al. reported the
simplified classical clinical tenderness score index for estimation of disease activity. One
of the problems in estimating activity of a polyarthritis is the number of possible sites of
inflammation. Ritchie and coworker’s index is calculated as the sum of observations on a
scale from 0 to three on examination of 15 index joints. The scaling of response from zero
to three makes this instrument still more complex than a simple count or number of joints
affected.
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After the description of Ritchie index in 72 and 18 patients in 1968, improved measures of
the activity of rheumatoid arthritis have been constructed from the same basic principle,
but in larger patient populations. Currently, another indicator of the same type (van der
Heide et al., 1990), Disease Activity Score (DAS-28) is one of the standard indices for
disease activity. In search for reliable but indicators, the 28 joint count (Fuchs et al., 1989)
has been developed to simplify the more time-consuming assessment of 66/68 joints
(Smolen et al., 1995; Table 3).
Table 3 The joints included in the simplified 28 joint count  (as in Smolen et al., 1995)
10 metacarpophalangeal joints
10 proximal interphalangeal joints
2 wrist joints
2 elbow joints
2 shoulder joints
2 knee joints
Health assessment Questionnaire (HAQ)
Another approach to estimating how the patient’s life is affected by the rheumatoid
arthritis was described by researchers from the Stanford University (Fries et al., 1980).
They presented a validated questionnaire type of tool with 9 questions addressing the
activities of the subjects (Table 4).
Table 4 Abilities covered by Disability index questionnaire (Fries et al., 1980)
1. Dressing and grooming
• Get clothes out of the closet
• Dress yourself
• Shampoo your hair
2. Arising
• stand up from a straight chair without arm support
3. Eating
• cut your meat
• lift a full cup/glass to your mouth
4. walking
• walk outdoors on flat ground
5. hygiene
• wash and dry entire body
• use the bathtub
• turn faucets on and off
• get on and off the toilet
6. reach
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• able to comb your hair
• reach and get down 5 lb (2 kg) bag of sugar from above your head
7. grip
• open push-button car-doors
• open jars that have been previously opened
• use a pen or pencil
8. activity
• able to drive a car
• able to run errands and shop
9. sex
• able to have sex (if applicable)
Each question 1 to 8 is evaluated on a scale: without difficulty, with difficulty, with help from
another person, and unable to do; question 9 is evaluated on a scale: without anyt difficulty,
somewhat uncomfortable, limited to certain positions or very uncomfortable, and impossible
because arthritis
This instrument, HAQ, has been one of the standards against which most later methods
have been evaluated.
Visual analogue Scale
A simple and popular method of recording pain is the Visual Analogue Scale
(Huskisson 1982). In VAS, a line is taken to represent the continuum of pain, the ends
defining the extremes of the experience, that is, “no pain” and “extreme pain”. Patients
mark the line at a point corresponding to their estimate of pain, and the distance from
point zero is taken to represent the severity of pain. This visual scale is independent of the
patients understanding, or verbal expressions, if the principle can be explained to the
patient has been used in multicultural settings (Bellamy & Buchanan 2005).
Patient Disability Index
To estimate disability caused by disease-related pain, Tait and coworkers described a
relativle simple tool covering seven fields of everday life (Tait et al., 1987). The
instrument consists of seven visual analogue scales ranging from 0 to 10 that, after
addition, give an index of up to 70. These life activities are: family/home responsibilities,
recreation, social activity, occupation, sexual behavior, self-care and life-support activity.
Patient disability index is a standard questionnaire-based intrument validated against
several psychometric intruments, including Beck’s Depression Inventory (Beck & Beck
1972)
Simplified Comprehensible Psychopathological Rating Scale - CPRS
In some patients, chronic pain is associated with depressive symptoms (Almay 1987).
The five self-assessment items chosen by Almay from the Åsberg et al, describe the mood
related changes the patients (Åsberg et al., 1978). The principle is to estimate on a visual
analogue scale following five items: sadness, bodily discomfort, inner tension,
concentration difficulties, and memory disturbancies. Almay studied 22 patients with
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neurogenic pain and 64 patients with idiopathic pain and compared them with 28 healthy
volunteers, showing 10 to 50 fold mean values in patients with chronic pain (Almay,
1987).
4.1.3. Characteristics of reactive arthritis
Reactive arthritis is a clearly microbially triggered inflammation of joints that usually has
a self-limiting course (Ahvonen et al., 1969; Aho et al., 1973; Rihl et al., 2006). Reactive
arthritis is usually seen in patients with genetic susceptibility that is associated to human
leukocyte antigen HLA B27, which according to the current nomenclature represents one
of the human histocompatibility complex class I antigens. The condition is also associated
with reactive inflammation in other tissues, such as the eye and the genitals. In spite of the
relatively benign natural course of reactive arthritis, a small subgroup of patients displays
a more aggressive disease that eventually leads to erosions in the joint structures. The
prevalence of reactive arthitis is 0.1% (Kvien et al., 1994; Braun et al., 1998).
The triggering agents vary, the most common being either Chlamydia trachomatis and
Chlamydia pneumoniae, in the genitourinary tract (Khan & Sieper, 2005) or pharynx
(Lauhio et al., 1992; 1994). Another common triggering event is gastroenteritis caused by
an enteropathogenic strain of gram-negative enterobacteria, for example, Shigella
dysenteriae, Salmonella enteritides, Yersinia enterocolitica or Campylobacter jejuni
(Khan & Sieper, 2005).
As opposed to rheumatoid arthritis, reactive arthritis is usually an asymmetric acute
oligoarthritis that most often has has a self-limiting course. The extraarticular
manifestations of reactive arthritis are balanitis and iritis that with arthritis form the triad
of Reiter’s disease.
4.1.4. Characteristics of osteoarthritis
Osteoarthritis -or better: degenerative joint disease or osteoarthrosis- is the most common
joint disease in humans that leads to significant expenses for the health care system
(Petersson & Jacobsson 2002, Lozada & Altman 2005). There is no causative agent
identified, but the absence of aggressive inflammation and presence of slow cartilage
destruction, radiographical narrowing of joint spaces, subchondral bone sclerosis,
osteophyte formation, and, eventually loss of function of the affected joint are typical
features. This commonly leads to need for prosthetic treatment by, for instance, hip
replacement surgery (Lozada & Altman, 2005). Depending on age group, the prevalence
of osteoarthritis is 10-18% (Reginster 2002; Woolf & Pfleger 2003).
In the synovial fluid of patients with osteoarthritis, the PMN effusion is relatively mild,
and generally, there is no high-grade inflammation that would have systemic
consequences in long term (Johnston Hough, 2005). Thus, in such patients rheumatoid
factor and cyclic citrullinated peptide antibodies are characteristically absent and
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erythrocyte sedimentation rate and C-reactive protein are typically within reference
values.
4.2 Inflammations of the periodontium
4.2.1. Histopathology of chronic periodontitis
A gingival sulcus is defined as an anatomical and physiological space having a depth less
than 4 millimeters. When the measurable depth of the sulcus increases to 4 millimiters, the
structure is considered pathological and is called a periodontal pocket. Formation of
pathological periodontal pockets is associated with chronic gingivitis that, when left
untreated, may proceed to chronic periodontitis. The pathological pocket provides a space
for various microorganisms that have been suggested to play a role in the perpetuation of
inflammation and subsequent tissue injury. Chronic inflammation involves a response by
the immune system: there are infiltrates of lymphocytes and polymorphonuclear
leukocytes that have the capacity to maintain the inflammatory reaction and cause
degradation of local connective tissue proteins. Ultimately, chronic periodontitis leads to
destruction of the periodontal attachment apparatus and loss of tooth (Pihlström et al.,
2005)
The immune response to chronic periodontitis involves recruitment of several cell types to
the site of inflammation: polymorphonuclear leukocytes, infiltrates of T lymphocytes and
macrophages, B lymphocytes and plasma cells (Pihlström et al., 2005). Generalised
periodontitis and local aggressive periodontitis have been reported to cause a systemic
CRP response when compared to subjects without periodontal inflammation (Salzberg et
al., 2006).
4.2.2. Indices of periodontal inflammation, inflammatory injury and tissue
destruction
Bleeding on probing.
Bleeding on probing can be recorded after probing the gingival sulci. The number of
bleeding surfaces is sometimes recorded only for selected index teeth, but can be recorded
and summated to a bleeding on probing index (BOP) that is the proportion of bleeding
examined surfaces (Greenstein et al., 1981; Cooper et al., 1983; deSouza et al., 2003).
Generally, absence of bleeding on probing is associated with absence of periodontal
inflammation (Lang et al., 1986; 1990).
Probing pocket depth (PPD)
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Periodontal probing pocket depth (PPD) is the distance from the gingival margin to the
bottom of the periodontal pocket, measured to nearest millimeter (Ainamo et al., 1982;
Armitage 2004a; 2004b). PPD reflects pocket formation and results from inflammatory
injury. However, PPD values are influenced by gingival edema, and do not take into
account gingival recession. Thus, PPD does not give the total amount of tooth attachment
loss. Concluding, PPD is better suited to measurement of inflammatory injury than
permanent tissue destruction.
Clinical attachment loss (CAL)
Clinical attachment loss (CAL) is the distance from the cemento-enamel junction to the
bottom of the periodontal pocket. Since CAL is measured from cemento-enamel junction
instead of from the margin of gingival soft tissue, local inflammatory swelling, edema or
gingival recession do not influece CAL. Thus CAL can be considered to be a measure of
permanent periodontal tissue destruction.
4.2.3. Prevalence of gingivitis and chronic periodontitis
Gingivitis and chronic periodontitis have been called the most prevalent inflammatory
condition that affects humans. Estimates of a prevalence of even 50 to 70 percent of
population have been given for gingivitis (Southerland 2006; Albandar & Rams 2002).
The more severe condition, chronic periodontitis has a smaller prevalence. Globally, there
are large populations whose periodontal status has not been characterized. From the
developed countries, however, there are data that can be considered reliable.
4.3 Matrix metalloproteinase gene family
Collagenases and gelatinases belong to a clan of peptidases that have a zinc-binding active
site and have a common catalytic strategy with bacterial thermolysin (Rawlings et al.,
2006). The original classification of collagenases and gelatinases has evolved to a
numbered system of soluble and membrane bound metalloproteinases. A summary of
matrix metallopeptidases is presented in table 5.
The active site zinc is protected by a propeptide and the enzyme can be activated by a
cysteine switch mechanism or by proteolytic removal of the activation peptide.
4.3.1. Substrate viewpoint - collagenases, gelatinases and stromelysins
In attempt to understand and learn more of enzymes working on the extracellular matrix,
the peptidases found were classified according to their substrates. This functional naming
convention lead to differentiation on collagenases and gelatinases. In the 1980’s a third
enzyme, stromelysin, with a different substrate profile was characterized and sequenced.
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4.3.2. Compartmental viewpoint– membrane-bound and soluble forms
Later, the nucleic acid approach proved to be a fruitful method to locate new
metallopeptidases of the family. This lead to the discovery of the metallopeptidases with
transmembrane domains and membrane anchor sequences. The transmembrane domains
are C-terminal and anchor sequences N-terminal. Anchors of GPI type have been
described (Milner & Cawston 2005). In a recent review article this group of enzymes are
termed membrane bound matrix metalloproteinases (MB-MMPs) (Page-McCaw et al.,
2007).
4.3.3. Metastructural clan classification – diversion and conversion from domain
structures
A prerequisite for synthesis is the accumulation of a sufficient amount of data to draw
conclusions on. The MEROPS – database (Rawlings et al., 1993; 2006) draws together
peptidase information over species boundaries. Here, it is possible to group homologous
peptidases in families and larger units called clans. Matrix metalloproteinases belong to
peptidases on type M (metallopeptidases), clan MA (metallopeptidases with a HEXXH
zinc binding motif) and family M10 (interstitial collagenases) in MEROPS peptidase
classification. The serine proteases involved in activation of some matrix
metalloproteinases belong to S1 family of peptidases in this classification. In 2007, Werb
and coworkers suggested another type of structural classification where MMPs are divided
in four groups: basic MMPs, MMPs with fibronectin-domain inserts, membrane-bound
MMPs and minimal domain MMPs (Page-McCaw et al., 2007).
4.3.4. Domains of matrix metalloproteinases
Matrix metalloproteinases contain following domains: signal peptide, propeptide, zinc-
binding domain, (an optional fibronectin domain), hemopexin domain, transmembrane
domain, and cytoplasmic domain. The domains and their relative lengths in collagenases,
gelatinases, stromelysins and MT-MMPs based on Swiss-Prot data bank are presented in
Figure 2. In addition to these MMPs, two MMPs with a C-terminal lipid anchor (MMP-17
and MMP-25) have been described. The individual domain lenghts are depicted in Figure
3 and Table 5.
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Figure 2 Typical domain structures of MMP subtypes.
Figure 3 Simplified domain structure of MMPs.
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Table 5  The domain lenghts of matrix metalloproteinases in Swiss-Prot Data Bank.
(December 2006).
IDNO Gene SP PRO ZBD FN1 FN2 FN3 HPX TM CTP ANCH CPP
P03956
P08253
P08254
Missing
Missing
Missing
P09237
P22894
P14780
P09238
P24347
P39900
P45452
P50281
P51511
P51512
Q9ULZ9
Missing
Q99542
Q99542
Q8N119
Missing
O75900
Q9Y5R2
Q9NPA2
Q9NRE1
Missing
Q9H239
MMP-1
MMP-2
MMP-3
MMP-4
MMP-5
MMP-6
MMP-7
MMP-8
MMP-9
MMP-10
MMP-11
MMP-12
MMP-13
MMP-14
MMP-15
MMP-16
MMP-17
MMP-18
MMP-19
MMP-20
MMP-21
MMP-22
MMP-23
MMP-24
MMP-25
MMP-26
MMP-27
MMP-28
19
29
17
17
20
19
17
31
16
19
20
41
31
38
18
18
24
1
52
21
17
22
80
80
82
77
80
74
81
66
89
94
91
90
90
90
79
79
120
78
103
86
72
100
176
112
187
173
181
131
187
193
173
177
430
235
230
203
188
411
188
312
221
206
172
205
49
49
49
49
49
49
194
195
191
192
192
191
193
192
191
196
196
196
198
190
190
217
196
198
193
21
21
21
21
21
20
23
22
19
22
1
1
38
23
4.3.5. Regulation of MMP gene expression
The regulation of MMP gene expression has been reviewed extensively in (Westermarck
& Kähäri 1999; Vaalamo 2000) and will be out of scope of this study and this review.
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4.3.6. Extracellular activation of matrix metalloproteinases
Generally, matrix metalloproteinases are synthesized and secreted in a latent proform and
are activated by endopeptidases or by oxidation in the extracellular environment. There are
several endopeptidases in various classes, mainly metalloendopeptidases and serine
endopeptidases that have been described to have the specificity to cleave the propeptide
activation site of the enzymes. Experimentally, also mercurial and gold (I) compounds have
been used to activate latent matrix metalloproteinases in vitro.
The physiological activation sequences have not yet fully been constructed, but, for instance,
MMP-14 has been shown to play a role in cell surface activation of MMP-2 (Strongin et al.,
1995). For some matrix metalloproteinases, the activating endopeptidase has been suggested
to be a chymotrypsin or trypsin like enzyme (Sorsa et al., 1997). Clearly, the activating
factors are, not necessarily produced by the secreting cell, but the process of activation may
need interplay of inflammatory cells and stromal cells of connective tissue.
4.3.7. Intracellular activation of matrix metalloproteinases
Some of the matrix metalloproteinases are activated already in trans-Golgi by and
endopeptidase called furin. These matrix metalloproteinases contain a furin cleavage
recognition site that is located between the cysteine switch and the zinc binding domain of
the enzyme. The recognition site that contains several positively charged amino acids has a
consensus sequence KRRK. Interestingly, MMP-23 has a type II membrane protein
sequence that is located in the N-terminal propeptide. The furin consensus site of MMP-23
is located but it does not seem to contain a consensus cysteine switch site P - R - C - [GN] -
x - P - [DR] - [LIVSAPKQ] (ProSite).
4.3.8. Role of matrix metalloproteinases in health and disease
Matrix metalloproteinases have a significant role as effector enzymes in the pathogenesis of
rheumatoid arthritis (Dayer, 2002; Firestein 2003). On the other hand, they are necessary for
wound healing, reprocessing of connective tissue in many physiological processes, and
migration of inflammatory cells across barriers between tissues. In their review, Werb and
coworkers represent five modes of action for MMPs: path clearing, generation of signaling
molecules, degradation of intercellular junctions or basement membranes, activation of
latent signals and regulation of active signals (Page-McCaw et al., 2007). Examples of these
latter functions are modification of vascular endothelial growth factor VEGF binding
properties (Lee et al., 2005) and cleavage of stromal-cell derived factor-1 (SDF-1) by MMP-
2 (McQuibban et al., 2001).
Interestingly, Vuorio and coworkers have shown that adenoviral induction of human MMP-
13 in mouse knee joints results in recruitment of inflammatory cells and increase in local
production of monocyte chemotactic protein-1 (MCP-1), the CC chemokine RANTES and
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interleukin-1β (Joroinen et al., 2003). This series of experiments is a further evidence of the
multiple roles of MMPs in inflammation.
In addition, V-J Uitto and coworkers have shown by in situ hybridization and that in chronic
adult periodontitis MMP-13 is involved in the growth of undifferentiated epithelial tissue
into the connective tissue stroma (Uitto et al., 1998).
Clearly, for an enzyme family of more than 20 members, there is no single function that
could be classified as purely pathological or purely physiological, but the functions of the
family perform a delicate interplay of effector molecules and their inhibition in the
physiological and anatomical context.
4.3.9. Disintegin metalloproteinases ADAMs and ADAM-TSs - the M12B family
Another major family of metalloendopeptidases - with a similar zinc requiring catalytic
structure that matrix metalloproteinases have - is called ADAMs (a disintegrin and a
metalloproteinase) (Wolfsberg et al., 1993).  They are structurally related to astacin (family
M12A) of crayfish and adamalysin (family M12B) of venomous pit viper Crotalus
adamanteus (Bode et al., 1993).  The first identified ADAM was a membrane fusion protein
PH30 (fertilin, ADAM-1 and ADAM-2) that was isolated from guinea pig sperm (Primakoff
et al., 1987).  The ADAMs having functions in fertilization and reproduction have also been
called reprolysins (Hooper, 1994). Today, the large family of known ADAMs and ADAM-
TSs shows a wide variety of functions from extracellular signal regulation to ectodomain
shedding of membrane-bound proteins.
Domain structure
The basic ADAM structure is a five-domain unit (Figure 4) with an aminoterminal
propeptide, metalloproteinase catalytic domain, a disintegrin domain and a cysteine-rich
domain  and a carboxy terminal transmembrane sequence (Primakoff & Myles, 2000;
Kaushal & Shah, 2000). In addition to these structures ADAM-TSs have a carboxyterminal
thrombospondin domain (Jones & Riley, 2005).
21
Figure 4 Basic structure of disintegrin metalloproteinases ADAMs and ADAM-TSs. Redrawn
after Jones & Riley 2005. S = signal peptide; PRO = propeptide; CATALYTIC =
catalytic domain; DIS = disintegrin domain; TS = thrombospondin-like domain; CRD
= cysteine-rich domain; EGF = EGF domain; TM = transmembrane sequence.
Functions of ADAMs in mammalian physiology
As to arthritides and osteoarthrosis, disintegrin metalloproteinases have been shown to have
both protective and accelerating roles. The expression of ADAM15 has been shown to be
increased in both OA (Böhm et al., 1999) and RA (Böhm et al., 2001). Deletion of
ADAM15 in mice leads to accelerated development of osteoarthrosis (Böhm et al., 2005).
Several ADAMs have been studied in models of rheumatoid arthritis (Böhm et al. , 2001;
Nagase & Kashiwagi 2003; Jones & Riley, 2005), osteoarthrosis (Böhm et al., 2001;
Appleton et al., 2007), and aseptic loosening of total hip prostheses (Ma et al., 2006).
ADAM17 has been reported to contribute to production of soluble TNF-α in rheumatoid
arthritis (Ohta et al., 2001). In conclusion, among the members of a fairly large enzyme
family their will be both overlapping of roles in both physiological and pathological
phenomena. This is going to be interesting, as being able to inhibit release of TNF-α, in
patients with rheumatoid arthritis represents a similar leap forward and up as inhibitors of
TNF-α were compared to inhibitors of collagenases (Newton et al., 2001).
4.4. Serine endopeptidases involved in activation of MMPs or direct tissue
injury
The serine proteases form a mechanistic class of endopeptidases that has several member
enzymes. Only the S01 family of chymotrypsin-like serine endopeptidases contains more
than 1000 molecules, 140 different S01 endopeptidases in Homo sapiens. This text
concentrates on those used in the experiments of Studies I-IV or discussed during the
preparation of the manuscripts. The domain structure of these enzymes is presented in
Figure 5.
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Figure 5 Domain structure of S01 serine proteinases and furin.
4.4.1 Elastase
PMN elastase is a neutral serine protease with an activity of cleaving peptide bonds C-
terminal to sequence AAPV (Ala-Ala-Pro-Val-X). In the MEROPS database it is classified
as (PA | S01.131) (Rawlings, 2006). Initially, an elastolytic enzyme was first desribed in
bovine pancreas the 1940’s  (Balo & Banga Nature 1949) and elastase activity was then
studied extensively in the 1950’s. The first report on polymorphonuclear leukocyte elastase
is from 1970 (Janoff Lab Invest, 1970).
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PMN elastase was isolated and purified by Janoff (Janoff Lab invest, 1973), and leukocytes
are the probable source of the elastase purifiied from purulent sputum (Twumasi & Liener
1977).
The mapping of the extended substrate binding site of PMN elastase with 4-nitroanilide
peptide substrates was reported in 1979 (Nakajima et al., 1979). Finally, cloning of PMN
elastase was reported under name of medullasin in 1987 (Nakamura et al., 1987). Because
elastase seemed to have the unique activity of degrading the elastic properties in human
tissues, already Balo and Banga, in 1949, presented a hypothesis that elastase could have a
connection to human pathology, they suggested that elastase would play a role in
atherosclerosis.
4.4.2 Cathepsin G
Cathepsin G, as opposed to other cathepsins that are cysteine proteinases, is a neutral serine
protease. It has a chymotrypsin-like activity of cleaving peptide bonds C-terminal to a
hydrophobic residue. In the MEROPS database it is classified as (Clan PA | Family S1 | ID
S01.133). Cathepsin G- is a typical serine endopeptidase of S1 family, having a charge-relay
mechanism of three amino acids forming the active site: His64, Asp108, and Ser201. Cathepsin
G has a chymotrypsin-like specificity for cleaving carboxyterminal to bulky or hydrophobic
residues. After biosynthesis, cathepsin G is stored in the primary granules of PMN
leukocytes and released on activation.
Neutral proteinases had been described by Hedin already in 1904 in bovine spleen (Starkey
& Barrett, 1976), but Starkey and Barrett isolated a neutral chymotrypsin-like proteinase
from post mortem human spleen and named it cathepsin G (Starkey & Barrett, 1976).
Cathepsin G was first isolated as an azocasein degrading neutral proteinase from human
spleen. The isolation and purification is described by Starkey and Barrett (Starkey & Barrett
1976) Later, several synthetic peptide substrates were developed for assay of cathepsin G
(del Mar et al., 1980) The cloning of cathepsin G was reported in 1987 (Salvesen et al. )
Domain structure of cathepsin G.
Like several other enzymes of the S01 group, cathepsin G has three main domains: an 18
amino acid signal peptide, a 2 amino acid activation peptide, and the S1 endopeptidase
domain of 222 amino acids (Figure 4). It contains three disulfide bridges and has a published
X-ray diffraction structure with a single domain (Greco et al., 2002).
Hypotheses of a role in human pathological processes
In 1978, Barrett suggested that the neutral proteinases of human leukocytes, elastase and
cathepsin G, might participate in the degradation of articular cartilage during the course of
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arthritis. At least the presence of polymorphonuclear leukocytes in the joint cavity would be
in keeping with this hypothesis. However, cathepsin G and elastase could only attack the
terminal non-helical parts of the collagen molecules (Barrett 1978).
4.4.3. Trypsin endopeptidases
Definition and taxonomy
Trypsin gene family codes for neutral serine proteases first characterized as enzymes of the
digestive tract. According to Oxford English Dictionary, trypsin is, at least in the English
literature, mentioned in 1897 in the context of pancreatic secretions. Most of the problems in
isolating insulin in the early decades of 20th century were due to trypsin and other
proteolytic enzymes of the exocrine pancreas (Banting 1925, Bliss 1982). Human trypsin-1
and trypsin-2 were isolated and N-terminally sequenced from pancreatic tissue in 1970’s (de
Caro et al., 1975; Figarella et al., 1975; Guy et al., 1978). In the MEROPS database trypsin
is classified as (Clan PA | Family S1 | ID S01).
Table 6 Human trypsins
Human
trypsins
MEROPS UNIPROT Alternative name Tissue
Trypsin-1 S01.127 P07477 cationic Pancreas
Trypsin-2 S01.258 P07478 anionic Pancreas
Trypsin-3 S01.174 P35030 mesotrypsin/brain trypsin Pancreas/brain
Trypsin-4 S01.237 P56730 neurotrypsin Brain, testis
The trypsins are synthesized as a proform, trypsinogen, that is proteolytically activated.
These endopeptidases of S1 family, display a typical charge-relay mechanism of three amino
acids at the active site: His63 – Asp107 – Ser200.
In trypsin-4 the distance between these key residues is the same, however, the insertion of an
amino terminal domain coding sequence in the gene results in active site residues His120 –
Asp164 – Ser257. The P1 substrate site specificity of trypsins is for peptide bonds with a
positively charged side chains on amino terminal side of the bond. Trypsins cleave more
readily after arginine than lysine.
Cloning and sequencing
The cloning of trypsin genes from pancreatic tissue was published in the 1980’s (Emi et al.,
1986). In 1990, cloning of an additional trypsinogen-3 gene was reported (Tani et al., 1990).
Trypsinogen-4 or neurotrypsin was cloned first from brain tissue (Wiegand et al., 1993;
Proba et al., 1998) and later from testes under name leydin (Poorafshar et al., 1999).
Trypsin-4 contains a separate amino terminal domain and thus differs from trypsins 1-3.
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Domain structure of trypsins
The domain structure of tryptases include three main domains: a signal peptide (15 aa), an
activation peptide (8 aa), and the S1 endopeptidase domain (221 aa). As an exception,
trypsin-4 contains an amino terminal domain that may play a role in regulation of enzyme
activity. The S1 endopeptidase domain of trypsin-1 contains three disulfide bridges and has
a published X-ray diffraction structure with a single domain for tetrameric trypsin-1
(Gaboriaud et al., 1996).
Table 7 Per cent of identical amino acids on trypsinogen domains
TR-1 TR-2 TR-3 TR-4
TR-1 ---- 89.5 85.0 82.6
TR-2 ---- ---- 87.0 85.0
TR-3 ---- ---- ---- 92.7
TR-4 ---- ---- ---- ----
Hypotheses of roles in human pathological processes
Trypsin-2 (tumour-associated trypsin-2) was isolated when looking for the target protease of
ovarian tumour-associated trypsin-inhibitor, TATI (Koivunen et al.1989), it proved to be
identical with the gene product of trypsinogen-2.  Later, tumour associated trypsin has been
shown to take part in the proteolytic activation of some matrix metalloproteinases (Sorsa et
al., 1997) and even peptidolytic cleavage of helical collagen molecules (Stenman et al.,
2005). The role of trypsins in carcinoma growth has been reviewed recently by groups of
Salo and Sorsa (Nyberg et al., 2006).
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Figure 6 Amino acid sequence alignment of trypsins 1 to 4. In the beginning of each row, there is
a 6-character code starting with ‘P’ or ‘S’. This is the protein sequence data bank
access number for each protein. For simplicity, the active site residues are marked by
underlined characters in bold type.
4.4.4. Furin
Human furin is an intracellular neutral serine protease with an activity of cleaving peptide
bonds C-terminal to sequence KX[R/K]K. In the MEROPS database it is classified as (SB |
S08.071).
In contrast to the other serine proteinases covered in this text, furin was first isolated by
nucleic acid cloning. Roebroek et al. reported having cloned a gene 5’ to the feline sarcoma /
Fujinama - Poultry Research Centre II sarcoma gene (fes/fps). Roebroek et al. called this
gene fes/fps upstream region gene, fur (Roebroek et al., 1987). A few years later, another
group reported having discovered the first mammalian homologue of killer exchange
proteinase, kexin, by a search of sequence databases. This Kex2p homologue enzyme, furin,
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showed sequence homology with the subtilisin-like catalytic domain (Fuller et al 1989).
Later, furin was shown to be expressed ubiquitiously in almost all human tissues studied.
Furin has an extended substrate recognition site for dibasic aminoacid sequences, the typical
sequence being RRKR. Interesetingly, this furin recognition site is found on several
members of the matrix metalloproteinase family.
4.5. The mevalonate pathway – a regulator of inflammation
Cholesterol synthesis in human cells is a well-characterized anabolic pathway. The rate-
limiting step of the pathway is biosynthesis of mevalonic acid from 3-hydroxy-3-
methylglutaryl coenzyme A (HGM-CoA). The well-characterized enzyme HMG-CoA
reductase catalyses the reaction. This pathway is subjected to complex regulation on several
levels: gene transcription, protein turnover, feedback inhibition etc (Brown & Goldstein
1980, 1990). The biosynthesis of cholesterol is a linear metabolic pathway that stepwise
leads to assembly of a 30-carbon precursor, squalene, from 5-carbon isoprenyl
intermediates.
In addition to cholesterol and cholesterol-derived vitamins, hormones, and other molecules,
mevalonate serves as a precursor to derivatives farnesyl and geranyl intermediates used in
posttranslational modification of several regulatory proteins.
4.5.1. Inhibition of the mevalonate pathway
Discovery of inhibitors of cholesterol synthesis from fungal metabolites in 1970’s (Endo et
al., 1976) lead in the course of the following decades to the development of the synthetic
inhibitors of HMG-CoA reductase, statins. After suitable compounds for human use were
found, they were used to treat hyperlipidemia, a major risk factor of cardiovascular disease.
The major site of endogenous cholesterol synthesis is the human liver. This was initially
thought to be the major site of action of statins. In fact, some of the statins concentrate in the
liver after peroral adminstration.
Statins proved to be efficient cholesterol lowering drugs, and simvastatin was shown to
reduce the risk of cardiovascular death and risk of undergoing a revascularization procedure
(4S study, 1994).
During the last decade, several compounds of the statin group have come to the market, as
summarized in Table 8.
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Table 8 Statin group of drugs & their classification (after Vaughan & Gotto 2003)
Drug Reduction
In TC(%)
Metabolism hydrophilic T1/2
Atorvastatin
Fluvastatin
Lovastatin
Pravastatin
Rosuvastatin
Simvastatin
25-45
16-27
16-34
16-25
33-46
19-36
CYP3A4
CYP2C9
CYP3A4
sulfation
CYP2C9
CYP3A4
No
No
No
Yes
Yes
No
13-30
0.5-3.0
2-4
2-3
19
1-3
TC = serum total cholesterol; T½ = half-life; CYP = Cytochrome P 450 – enzyme
In addition to cholesterol lowering, inhibition of the mevalonate pathway had been
suggested to influence many physiological and pathophysiological processes (Goldstein &
Brown, 1990). Several of these are the result of the inhibition of the cholesterol-independent,
but mevalonate-dependent lipid modifications of key regulatory proteins.
4.6 Geranylgeranyl cysteine lipid anchors
The postranslational geranylgeranylcysteine lipid modifications belong to the group of
protein modifications where the properties of the protein are changed through
isoprenylation. Isoprenyl units are five-carbon units that are the repeated structure in
farnesyl pyrophosphate and geranylgeranyl pyrophosphate, the donors in the prenylation
process.
4.6.1 Discovery of lipid anchors in proteins
Covalent lipid modification of proteins was first described in the early 1970’s (Hantke &
Braun 1973). Hantke and Braun demonstrated attachment of fatty acids to the α-amino
group of aminoterminal cysteine in an E. coli outer membrane protein. In addition, they also
described a diacylglycerol modification in the side chain-thiol of the aminoterminal cysteine.
Subsequently, in chick embryo cells infected by Sindbis virus, radioactive palmitate label
was shown to be associated with viral proteins (Schmidt et al., 1979).
Shortly after, prenylation of a mammalian protein was described (Schmidt et al., 1984).
During the following decades, several other types of covalent lipid modifications on proteins
were decsribed.
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The first report on an isoprenyl modification of a peptide is from the late 1970’s, when a C-
terminal farnesyl modification of a fungal mating peptide was described (Kamiya et al.,
1978).
4.6.2. Types of lipid anchors
The covalent lipid anchors on proteins include S-acylation, S-diacylglycerol modification,
cholesterol ester modification, glycolipid modification and isoprenylation (Resh 1996,
Magee & Seabra 2005).
4.6.3. Mevalonate derived lipid anchors
The invention of inhibitors of HMG-CoA reductase allowed the study of non-cholesterol
dependent effects of blocking the mevalonate pathway (Endo et al., 1976, Brown &
Goldstein 1980). In mammalian cells, the prenylated proteins were discovered mostly
through database searches, after the characteristic CAAX sequence motif for isoprenylation
was found. Most of these proteins belonged to the family of small GTP-binding proteins,
regulator molecules structurally related to the small GTP-binding protein, encoded by the
gene ras, named after Rous avian sarcoma (Casey 1992, Resh 1996, McTaggart, 2006). The
isoprenyl modification of these proteins involves transfer of a farnesyl (C15) or a
geranylgeranyl (C20) group to a cysteine residue from farnesyl pyrophosphate or geranyl
geranyl pyrophosphate, respectively (Casey 1992, Resh 1996, McTaggart 2006).
4.6.4. Small GTP-binding proteins with lipid modification
The family of small GTP-binding proteins is a large family of intracellular, membrane
associated signal transduction-related proteins that is involved in the regulation of a
widevariety of cellular functions. The central mechanism of small GTP-binding proteins
revolves in cycling between a GDP-bound inactive form and an active GTP-bound form. In
their active form, small GTP-binding proteins bind to effector molecules to regulate them by
conformation-specific interactions (Etienne-Manneville & Hall 2002; Rikitake & Liao 2005;
Jaffe and Hall 2005).
The location and activity of small GTP-binding proteins are regulated by the lipid
modification that targets them to the plasma membrane. One of the principal regulatory
mechanisms is the covalent lipid modification of these molecules.
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4.6.5. Biological effects of small GTP-binging proteins
The biological effects of inhibition of the mevalonate pathway are numerous (Takai et al.,
2001; Cordle et al., 2005). The farnesylated and geranylgeranylated small GTP-binding
proteins take part in several processes from cell cycle regulation to migration, phagocytosis,
and generation of reactive oxygen species by NADPH oxidase (Takai & al., 2001; Jaffe &
Hall 2005, Hordijk 2006).
Thus, total inhibition of the small GTP-binding proteins would be incompatible with life, as
shown by growth arrest of mevalonate-starved cells (Brown & Goldstein, 1980). Partial
inhibition, however, may be the mechanism behind several beneficial effects of statins.
4.7 Anti-inflammatory effects of statins
During the recent years, the non-cholesterol dependent effects of statins have been called
also pleiotropic effects. The entry of word pleiotropic in Oxford English Dictionary
mentions use of the word in the 1930’s referring to mutations affecting several phenotypes.
The word ‘pleiotropic [regulatory] effect’ first appears in litterature databases in connection
with cholesterol metabolism in reports of Sinensky and coworkers (Leonard & Sinensky
1988, Leonard et al., 1990) in the meaning that 25-hydroxycholesterol has a pleiotropic
effect on transcription of genes for enzymes of cholesterol synthesis. Defined in a broader
sense, pleiotropic refers to any additional effects produced by a gene, gene product,
metabolite or a drug compound. In the context of this review, we use the term pleiotropic to
describe the non-cholesterol-dependent effects of statins.
Statin group drugs have been shown to exert numerous effects on the immune system. First,
they decreased the levels of plasma C-reactive protein a prospective study of 5742 patients
(Ridker et al., 2001). This could be mediated by inhibition or down-regulation of the IL-6 –
induced C-reactive protein acute phase response in the liver.
Second, Mach has demonstrated stat statins decrease the expression of major
histocompability complex II genes that are a requisite of T-cell activation by antigen
presenting cells (Kwak et al., 2003). Third, the statins coud have a regularoty limiting effect
on leukocyte migration by, for instance, reducing the monocyte chemoattractant protein-1
(MCP-1) in chronic inflammatory lesions (Martìn-Ventura et al., 2005).
Fourth, and finally, the effect of statins on inflammation might be mediated by shifting the
T-cell differentiation from Th1 towards Th2 type cells (Youssef et al.; 2002). There is a
difference in the potency of the statins in decreasing serum cholesterol (Vaughan & Gotto
2003). The hypocholesterolemic effect of statins is clearly separate of the anti-inflammatory
effect that is mediated by the isoprenyl members of mevalonate pathway (Liao & Laufs
2005).
31
4.7.1. Signal transduction
With the effects of protein prenylation revealed, and the large group of small GTP-binding
proteins involved in many inflammation related processes, it appeared that prenylation of the
small GTP-binding proteins might be the regulatory mechanism that mediates the effects of
inhibition of the mevalonate pathway. As the number and functions of these proteins are
numerous, it will take time and effort until the regulation and details of mechanisms are fully
understood.
4.7.2 Sepsis
Interestingly, in a clinical setting cohort study, it has been shown that statin medication is
associated with better patient outcome in sepsis (Hackam et al., 2006). This interesting
result, however, is based on epidemiological evidence, and the mechanistic links possibly
connecting statin administration to patient outcome remains obscure. For instance, wheteher
the effect is mediated through the small GTP-binding proteins or a direct,
immunomodulatory effect on antigen presenting cells, is unclear (Arora et al., 2006).
Definitely, these actions of statins need further reasearch in both cell biological and clinical
settings.
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5. AIMS OF THE PRESENT STUDY
STUDY I
Inflammation may have a priming and activating effect on polymorphonuclear white blood
cells. Our hypothesis was that the polymorphonuclear cells recruited to the site of
inflammation could be in an activated state when compared to similar cells circulating in
peribheral blood. We measured two serine proteinases capable to degrade connective tissue
components in these two compartments.
• To study the role of cathepsin G and elastase in peripheral blood and inflamed
synovial fluid of patients with two types of arthritis.
STUDY II
Chronic inflammation in joints may lead to desctruction of the joint structure. The final
effectors of this are collagenases. Our hypothesis was that the newly cloned collagenase-3
could be involved in the process. We selected immunological and biochemical methods to
study whether collagenase-3 is present in the synovial tissue of patients with arthritis.
• To study the role or collagenase-3 (MMP-13) in inflammation of arthritis
STUDY III
The tetracycline hypothesis stated that tetracycline compounds could inhibit collagenases
and gelatinases. To examine the effect of tetracyclines in vivo we selected patients with
rheumatoid arthritis for a 12-week doxycycline treatment in a small pilot type study. We
chose to measure both biochemical markers and known psychosocial indicators to monitor
patient health indeces.
• To study the doxycycline hypothesis of matrix metalloproteinase inhibition in
arthritides: is there an alleviating effect?
STUDY IV
Chronic inflammation has been suggested to be a risk factor of cardiovascular disease. Our
hypothesis was that the pleiotropic effects of statins could contribute to the their action in
prevention of cardioascular disease. We chose a cohort of patients with periodontitis to study
whether chronic statin treatment is associated with less periodontal inflammatory injury. To
account for advanced disease, we developed a clinical index that better describes the risk.
• Study the signs of inflammatory injury in cardiovascular risk patients receiving
treatment for periodontitis – the statin effect.
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6. EXPERIMENTAL PROCEDURES
6.1 Patients and methods (I)
6.1.1 Patients (I)
Eight patients (mean age: 36 years, range 26 to 53) with typical ReA (Nordström et al.,
1989) and ten patients (mean age: 55.8 years, range 35 to 79) who met the 1987 revised
criteria for RA (Arnett et al., 1988) were accepted for the study (Study I, Table I). All ReA
patients were rheumatoid factor (RF) negative and all except one (no 15) were HLA-B27
positive. All patients initially presented with a preceeding microbial infection that also was
identified in all but two patients (patients nos. 11 and 15). All except one patient (no. 14)
had a self-remitting nonerosive disease that did not require treatment with disease modifying
anti-rheumatic drugs (DMARD). Patient no. 14 presented with prolonged symptoms
including peripheral erosions in hands and feet as well as iritis, that eventually lead to
treatment with methotrexate.
Five of the 10 RA patients were RF positive, nine had erosions and all were on DMARD
treatment (Study I, Table I). From all patients at least 10 ml of freshly drawn SF from an
arthritis knee joint and 20 ml of peripheral blood (PB) were delivered to the laboratory for
further processing in sterile heparin-containing syringes. Bone marrow smears from healthy
controls were stained for cathepsin G and elastase (Fig.3), to detect the cellular origin and
intensity of positive cells on bone marrow level.
6.1.2 Immunohistochemistry (I)
Cytospin specimens (SF, PB, bone marrow smear) were fixed in acetone for 5 minutes at +4
°C, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in
methanol for 30 minutes. The specimens were then treated serially with normal goat or horse
serum (dilution 1:150, Vector Laboratory, Burlingame, CA, USA) for 20 minutes;
polyclonal rabbit anti-human neutrophil cathepsin G antiserum (1:300, Dako Co.,
Carpinteria, CA, USA), monoclonal mouse anti-human neutrophil elastase antibodies
(1:150, Dako Co., Carpinteria, CA, USA), polyclonal rabbit anti-human α1-ACT
immunoglobulin (1:200, Dako Co., Carpinteria, CA, USA) or polyclonal rabbit anti-human
α1-PI immunoglobulin (1:200, Dako Co., Carpinteria, CA, USA) for 60 minutes;
biotinylated goat anti-rabbit or horse anti-mouse igG for 30 minutes; avidin-biotin-
peroxidase complex (Vector Laboratories Burlingame, CA, USA) for 30 minutes; and a
combination of 3,3’-diaminobenzidinetetrahydrochloride (Sigma Chemical Co., St. Louis,
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MO, USA) and hydrogen peroxide (Hsu et al., 1981). All the specimens were counterstained
with hematoxylin. All incubations were performed at room temperature. The staining
controls were omission of primary poly- or monoclonal reagent in the staining sequence, use
of inappropriate antibodies in the second stage, and staining for endogenous peroxidase with
DAB reaction only. At least ten fields per slide were evaluated (200 cells/field) with a light
microscope (Nordström et al., 1985).
6.1.3 Measurement of serine proteinase activities (I)
The measurement of cathepsin G and elastase activities was performed in triplicate by N-
Suc-Ala-Ala-Pro-Phe-p-nitroanilide (SAAPFNA) and N-Suc-Ala-Ala-Val-p-nitroanilide
(SAAVNA) as substrates (both peptide substrates were from Sigma Chemical Co., St.Louis,
MO, USA), respectively, and N-(2-hydroxyethyl) piperazine-N’-(ethanesulfonic acid)
(HEPES, Sigma Chemical Co., St.Louis, MO, USA) with 0.1% polyoxyethylene 23 lauryl
ether (Brij 35, Sigma Chemical Co., St.Louis, MO, USA) as a buffer solution (pH 7.4).
Dilution series of purified human neutrophil cathepsin G and elastase (Sigma Chemical Co.,
St.Louis, MO, USA) were used as positive controls, and substrate and buffer samples as
negative controls. 10 ml of samples or controls was applied to PolySorp ELISA-plate
(NUNC, Roskilde, Denmark), and a mixture of 10 ml of SAAPFNA or SAAVNA (20 mM
in dimethyl sulfoxide) and 80 ml HEPES with 0.1% Brij 35 was added. The reaction was
performed in humidified air at +37°C. Absorbance at 405 nm was measured at 10 minute
intervals with Labsystems Multiscan PLUS model 313 Reader (Labsystems & Flow
Laboratories, Helsinki, Finland) with correction for background values. Elastase and
cathepsin G values (IU/L) were obtained from calibration curves based on a plot of initial
velocities (v0 = ∆OD405nm / ∆t20-50 min) of enzyme standards.
6.1.4 Dot-immunostaining (I)
Cathepsin G, elastase, α1-PI and α1-ACT (Sigma Chemical Co., St.Louis, MO, USA) were
diluted in 0.05 M Tris-HCl - 0.2 M NaCl – 0.005 M CaCl2, pH 7.5, to make the
concentration range from 1 mg/ml to 0.0017 mg/ml. The volume of the samples blotted onto
nitrocellulose membrane (Bio-Rad Laboratories, Richmond, CA, USA) was 3 ml. After
incubation with 3% gelatin (Sigma Chemical Co. St.Louis, MO, USA) block solution and
washing with 0.1% Tween-80- TBS (0.02 M Tris-HCl – 0.15 M NaCl, pH 7.5), blotted
membranes were incubated with respective antibodies described above for one hour. After
washing with 0.1% TTBS three times, the membranes were incubated with alkaline
phosphatase conjugated goat anti-rabbit or –mouse IgG (Sigma Chemical Co. St.Louis, MO,
USA) for 30 minutes. After washing with 0.1% TTBS three times, alkaline phosphatase
binding sites were revealed in 10 ml alkaline phosphatase buffer (0.1 M Tris-HCl – 0.1 M
NaCl, 0.005 M MgCl2, pH 9.5) with a combination of 20 ml nitro blue tetrazolium solution
(50 mg/ml in 70% dimethylformamide, Sigma chemical Co., St.Louis, MO, USA) and 10 ml
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5-bromo-4-chloro-3-indolyl phosphate solution (50 mg/ml in 70% dimethylformamide,
Sigma Chemical Co. St.Louis, MO, USA)
6.1.5 Statistical analysis (I)
The mean ± standard deviation was used to express dispersion. The significance of the
differences between mean values was tested by use of Mann-Whitney U test. Linear
regression analysis was used to study the relationship between two variables. Analyses were
performed using Statistix 4.0 statistical software package (Siegel 1992).
6.2 PATIENTS AND METHODS (II)
6.2.1 Patients and samples.
Synovial tissue specimens were obtained from 16 consecutive patients at the time of joint
replacement surgery or diagnostic/therapeutic arthroscopy (Study II, Table 1). Six of these
patients (all women, mean age 52.5 years, age range 37-73) had RA (Arnett et al., 1988),
with a mean disease duration of 8.8 years (range 5-14 years), and 7 of these patients (6
women and 1 man, mean age 65 years, age range 48-90) had OA (Altman et al., 1986), with
a mean disease duration of 8 years (range 5-13 years). Samples were also available from 1
patient with osteochondritis dissecans, 1 with luxation of the patella, and 1 with a ruptured
meniscus. Diagnoses of the last 3 conditions were proved by arthroscopy.
Ten synovial samples were obtained from the knee, 2 from the proximal interphalangeal
joint, 1 from the metacarpophalangeal joint, 2 from the wrist, and 1 from the shoulder joint.
All samples were snap-frozen, embedded in Tissue-Tek OCT compound (Lab-Tek Products,
Elkhart, IN), and stored at-70°C until used.
6.2.2 Cytospin preparation of neutrophils.
To exclude cross-reaction of the anti-MMP-13 antibody with MMP-8 collagenase, isolated
leukocytes were used as a known MMP-8-positive control. Polymorphonuclear leukocytes
were isolated from the buffy coat layer of a 20-ml blood sample by a standard protocol in
microfuge tube scale (Konttinen et al., 1991). A viability count was obtained in 0.2% trypan
blue in phosphate buffered saline, and cells were adjusted to a concentration of 0.6 × 106/ml.
Cytospin preparations were made at 6.0 × 104 cells/slide. Slides were air dried for 10
minutes and fixed in –20°C methanol for 10 minutes.
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6.2.3 Immunohistochemical staining.
Avidin-biotin-peroxidase complex (ABC) staining (Hsu et al., 1981) was utilized using
Vectastain Elite ABC rabbit kit (Vector, Burlingame, CA). Six micrometer-thick cryostat
sections were applied to gelatin-formalin-coated slides, and fixed in acetone for 5 minutes at
4°C.Endogenous peroxidase activity in the tissue sections and cytospin preparations was
inhibited with 0.3% H2O2 in methanol for 30 minutes. Samples were incubated serially at
22°C in 1) normal goat serum (diluted 1:60) for 30 minutes, 2) primary rabbit anti-human
MMP-13 antibodies(diluted 1:500) for 60 minutes, 3) biotinylated goat anti-rabbit IgG
(diluted 1:133) for 30 minutes, 4) ABC (diluted 1:100) for 30 minutes, or 5) 3,3’-
diaminobenzidine tetrahydrochloride (DAB; Sigma, St.Louis, MO) in 0.006% H2O2 solution
in TBS (0.05M Tris, 0.15M NaCl, pH 7.4) followed by a wash in tap water. Consecutive
sections or cytospin preparations were counterstained with Harris hematoxylin or were not
counterstained. Slides with counterstaining were repeatedly washed in tap water. Finally,
sections or cytospin preparations were dehydrated, cleared in xylene, and mounted in a
synthetic mounting medium (Diatex, Becker, Märsta, Sweden). Morphometry was done
using an ocular counting square (20 squares × 20 squares) and an oil immersion objective
(1,000- magnification). At least 500 of each of synovial stromal cells, synovial lining cells,
and endothelial cells were counted to estimate the ratio of positive cells. Lymphocytes were
excluded from the cell counts (Konttinen et al., 1981). A 0.1% solution of bovine serum
albumin (Sigma) in TBS was used for dilution of the primary antibodies and sera. Between
steps (except after incubation in normal goat serum), the slides were washed 3 times for 5
minutes in TBS. Routine controls were omission or use of normal rabbit IgG (no. X903;
Dako, Glostrup, Denmark) instead of the primary antibody and exposure of the tissue
sections to DAB and H2O2 (for endogenous peroxidase).
6.2.4 Double staining for MMP-13 and CD68.
ABC-alkaline phosphatase-anti-alkaline phosphatase (APAAP) double staining was
performed, and the color reactions were developed as described in detail elsewhere (Hsu et
al., 1981; Cordell et al., 1984; Konttinen et al., 1992). Briefly, consecutive 5 µm-thick
cryostat sections from 2 of the synovial specimens used for MMP-13 staining were
processed for staining of MMP-13 according to the protocol for the ABC technique (Hsu et
al., 1981) up to the step where the slides were rinsed in tap water. Then, the slides were
washed with TBS (0.05M Tris - 0.15M NaCl, pH 7.4), and incubated at room temperature in
1) normal rabbit serum (diluted 1:50) for 1 hour, 2) mouse anti-human CD68 IgG (dilution
1:50) for 1 hour, 3) rabbit anti-mouse IgG (dilution 1:25) for 1 hour, or 4) APAAP solution
(dilution 1:25) for 1 hour. Alkaline phosphatase was visualized after treatment with BCIP
(Sigma no. B-0274) and nitroblue tetrazolium (Sigma no. N-6876) in alkaline phosphatase
buffer for 10 minutes at room temperature, covered from light. Endogenous alkaline
phosphatase activity was inhibited by including 0.003M levamisole (Sigma no. L-9756).
Finally, the slides were dehydrated, cleared, and mounted. Reagents for the double-staining
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protocol were from Dako A/S, unless otherwise specified. Between each step, the sections
were washed 3 times for 5 minutes with buffer.
6.2.5 Preparation of the antiserum.
The immunization procedure is described elsewhere (Freije et al., 1994). Briefly,
recombinant human MMP-13 was produced in Escherichia coli, and 8M urea was used to
solubilize the insoluble fraction of the cell lysate. Then, 1 ml of the 8M urea extract was
electrophoresed through a 12% polyacrylamide gel, and the portion of the gel containing the
recombinant protein was excised, ground, and incubated with 2 ml of deionised water at
37°C for 20 hours with sporadic vortexing. Next, 1 ml of sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE)-purified protein was used to immunize a
New Zealand white rabbit according to the method described by Vaitukaitis (Vaitukaitis,
1981). The rabbit was bled 6 weeks after the injection, and IgG were purified by
chromatography through DEAE-cellulose (Whatman DE52; Whatman, Kent, UK),
equilibrated, and eluted with 0.02M phosphate buffer, pH 7.2. The IgG concentration was
1µg/µl. Preliminary experiments examining the possible cross-reactivity with other MMPs,
including MMP-1, MMP-8, and stromelysins, failed to reveal any significant cross-
reactivity.
6.2.6 Absorption control tests.
The specificity of immunoreaction was tested in 1 RA and 1 OA sample by preabsorbing the
anti-MMP-13 with an excess of antigen, as described previously (Van Noorden, 1986).
Briefly, the maximum reproducible dilution (1:1,000) of anti-MMP-13 for the tissue was
determined, and this working dilution was incubated with 0.1 nmoles of the antigen
overnight at 4°C. This presaturated antibody dilution was then used in place of the primary
antibody.
6.2.7 Extraction of proteolytic enzymes.
Synovial tissue specimens were stored at –70°C until used. No cartilage was included in the
samples to be used for tissue extraction. Tissue pieces were homogenized in 3 volumes of
TBS-1M MgCl2, extracted on ice for 1 hour, and clarified by centrifugation. The supernatant
was dialyzed against 3 changes of TNC (0.005M CaCl2 in TBS, pH 7.5) and stored at –70°C
until analysed (Konttinen et al., 1991).
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6.2.8 Calculation of the isoelectric point (pI).
Calculations were performed using pKa values for amino acids. The amino acid sequences
for MMP-1 and MMP-13 were retrieved from the Swiss-Prot protein databank, signal
peptides were removed with a text editor program, and charges were calculated for
procollagenases and collagenases using the Microsoft Excel 5.0 spreadsheet program.
Possible sialic acid residues in glycosylated forms of MMP-1 and MMP-13 were not taken
into account in the calculations of the apparent pI (Segel 1968; Ribeiro & Sillero 1990;
Henriksson et al., 1995). The charges calculated were used to choose the pH for the
nondenaturing electrophoresis buffer, since molecules of approximately the same size but
different charge would show different electrophoretic mobilities.
6.2.9 Electrophoresis.
Three buffer systems were used for separating MMP-1 and MMP-13 in the extracts. First,
SDS-PAGE was run as described by Laemmli (Laemmli 1970), without reduction. Second,
low pH Triton-acid-urea gels (TAU gels, 10%) were run essentially as described by Smith
(Smith 1994). Third, high-pH gels were run in am Ornstein-Davis buffer system using 7.5%
gel (Davis 1964; Ornstein 1964). A minigel apparatus from Bio-Rad (Richmond, CA) was
used for all gels.
6.2.10 Protein blotting and immunostaining.
Synovial tissue extracts were prepared for the different buffer systems, electrophoresed, and
blotted onto nitrocellulose filter. Proteins from SDS-PAGE gels were blotted in routinely
used Tris-glycine buffer in a Bio-Rad Mini-TransBlot system (Laemmli 1970; Towbin et al.,
1979). From the TAU gels, proteins were capillary blotted overnight at room temperature.
After a brief soak in 2.3%(weight/volume) SDS-5% (v/v) 2-mercaptoethanol, blotting from
Ornstein-Davis native gels was carried out with 0.1% SDS added to the transfer buffer
(Waterborg & Harrington 1987). Nitrocellulose filters were blocked with 3% (w/v) gelatin,
washed in TBS, and incubated overnight with rabbit anti-human MMP-13 (1:500) or rabbit
anti-human MMP-1 (1:500). Goat anti-rabbit IgG horseradish peroxidase conjugate was
diluted to 1:500, and the blots were developed using 4-chloro-1-naphthol (Sigma) as a
chromogen.
6.2.11 Collagenase assay.
Soluble rat tail tendon type I and bovine cartilage type II collagens were purified by pepsin
extraction and selective salt precipitation at acidic and neutral pH, as described in detail
elsewhere (Miller & Rhodes 1982). Recombinant human MMP-13 was activated with
0.001M aminophenyl mercuric acetate (APMA) for 30 minutes and incubated with type I
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and type II collagen at a concentration of 1.5 µM for 3 hours at 22°C. The enzyme reaction
was terminated by boiling for 5 minutes after addition of sample buffer without 2-
mercaptoethanol. Intact collagen α chains and their ¾ (αA) and ¼(αB) degradation products
were separated by 11% SDS-PAGE (Turto et al., 1977). The percentage of collagen
degraded was estimated by image analysis (Molecular Analyst; Bio-Rad) of Coomassie
blue-stained gels. Specifically, the gel was scanned on the hard disk of the computer, intact
monomeric collagen bands were marked, and the marked areas were analysed for pixel
intensity. The scores of ¾ fragments were multiplied by 4/3 to compensate for the ¼
fragment not scanned, and the percentage from the total (intact band score plus degraded
band score) was calculated.
6.2.12 Production and purification of human recombinant MMP-13.
Human MMP-13 was produced using a vaccinia virus expression system as previously
described (Freije et al., 1994). Vaccinia virus-expressing human MMP-13 was obtained
using a plaque selection system (Blasco & Moss 1995). Plasmid pRB-col3 was obtained by
inserting an EcoRl/HindIII fragment containing the gene downstream of a vaccinia virus
synthetic early/late promoter, in plasmid pBR21. Confluent monolayers of CV-1 cells in T25
flasks were infected with 1 plaque forming unit (PFU) per cell of vaccinia virus vRB12
clone a4 and transfected with 10 µg of plasmid pRB-col3. At 2 days postinfection, the
progeny virus was harvested. The recombinant, termed VV-col3, was selected by 2
consecutive rounds of plaque purification on BSC-1 cell monolayers. For production of the
recombinant protein, preconfluent BSC-1 cells in 900-cm2 roller bottles were infected with
wild-type vaccinia virus (strain WR) or VV-col3, at a multiplicity of infection of about 5
PFU/cell. The medium was harvested at 24 hours postinfection.
The recombinant protein was purified from the culture medium by chromatography onto an
S-Sepharose fast flow column (2.5 × 10 cm; Pharmacia, Uppsala, Sweden) equilibrated in
0.02M Tris HCl, pH 7.2, 0.005M CaCl2, 0.05% NaN3. The matrix was washed in the same
buffer to background A280 readings, followed by another wash with the same buffer with
0.2M NaCl to remove impurities. Finally, the column was eluted with the same buffer with
0.5M NaCl, and the fractions containing pro-MMP-13 were identified by analysis in SDS-
PAGE.
6.2.13 Assessment of the inhibition characteristics of the recombinant MMP-13.
Briefly, autoactive MMP-13 was incubated with type I and type II collagen and analysed as
described above. Autoactivation refers to an apparently spontaneous conversion of pro-
MMP-13 into its enzymatically active form in the absence of proteolytic activators or
organomercurials (Knäuper et al., 1996). Collagenase activity was determined in the
presence of doxycycline, clodronate, pamidronate, and D-penicillamine, at a wide range of
concentrations. The concentrations were chosen to also cover those attained in vivo in
patients receiving regular treatment with these drugs.
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6.2.14 Statistical analysis.
BMDP 7.01 software was used for the statistical calculations. P values were estimated using
the Mann-Whitney test for unpaired groups.
6.3 Patients and methods (III)
The study was performed at the outpatient clinic of the Department of Rheumatology,
Helsinki University Central Hospital. The open label study protocol was approved by the
local ethics committee prior to initiation. The patients gave their informed consent in
writing. The 12 enrolled RA patients fulfilled the 1987 ACR criteria (Study III, Table 1)
(Arnett et al., 1988). All received 150 mg/day of doxycycline for 3 months. Patients were
allowed to continue their disease modifying anti-rheumatic drug (DMARD) therapy, which
had been kept stable for the last 3 months prior to the study. Stable per oral corticosteroids
were allowed up to 10 mg prednisolone (or equivalent) per day. Inclusion criteria were:
functional class I–III (Hochberg et al., 1992), signs of active disease as defined by a
sedimentation rate of > 28 mm/h or CRP > 15 mg/l and a joint tenderness score index
showing at least six tender joints (Study III, Table 1) (Ritchie et al., 1968). Exclusion criteria
were other ongoing antibiotic treatments, pregnancy, malignancy or tetracycline allergy.
Blood (Hb, ESR and CRP) and stimulated saliva samples were collected at baseline, at 6
weeks and at 12 weeks. In addition, the following assessments were made: a four-stage
functional classification (Hochberg et al., 1992); joint score index (measuring tenderness in
proximal interphalangeal, metacarpophalangeal, wrist, elbow, shoulder, acromioclavicular,
sternoclavicular, jaw, cervical, hip, knee, talocrural, talocalcanear, metatarsophalangeal and
toe joints on each side; scores 0–3) (Ritchie et al., 1968) performed by the principal
investigator; the Health Assessment Questionnaire (HAQ) (Fries et al., 1980); Visual
Analogue Scale of Pain (VAS) (Huskisson 1982); Pain disability index (PDI, 7 VAS
variables) (Tait et al., 1987); and Comprehensible Psychopathological Rating Scale (CPRS,
5 VAS variables) (Almay 1987).
Collagenolytic activity was measured against soluble native/triple helical collagen type I
monomers. Native type I collagen was extracted from human skin and further purified by
selective salt precipitation at acid and neutral pH. The purity of type I collagen substrate was
examined by cyanogen bromide cleavage peptide analysis.
Salivary samples were centrifuged and supernatants assayed for collagenase activity by the
quantitative SDS-PAGE laser densitometric method originally described by Turto et al.
(Turto et al., 1977). Total collagenase activity was measured in the presence of 1 mM
aminophenylmercuric acetate (APMA) and the endogenously in vivo activated collagenase
activity without APMA. APMA is an optimal organomercurial activator of latent
collagenases, because it removes the thiol group of the Cys73 from the active site zinc and
thus releases the fourth coordination site of it (Springman et al., 1990). The salivary samples
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were incubated with soluble native 1.5 µM type I collagen at 22°C for 48 h. Incubation was
stopped by addition of a modified Laemmli’s sample buffer containing 0.040 M EDTA,
followed by immediate heating at 100°C for 5 min. Subsequently, the degradation products
were separated by SDS-PAGE on 10% T 2.6% C gel. The gels were stained with Coomassie
brilliant blue and destained in 5% acetic acid –10% methanol in water (v/v). The destained
gels were quantified by destitometric scanning using the LKB Ultrascan Laser
Densitometric model 2202. The values representing αA-chains were multiplied by 4/3 and
their proportion of total collagen in the sample was used as a measurement of collagenase
activity, which is expressed as per cent type I collagen degraded.
Collagenase enzyme protein was demonstrated using Western blotting. The samples were
treated with Laemmli’s buffer, pH 6.8, containing 0.005 M dithiothreitol (DTT) and heated
for 5 min at 100°C. High- and low-range prestained SDS-PAGE standards (Bio-Rad,
Richmond, Calif.) were used as molecular weight markers. The saliva samples were
separated on 8–10% SDS-PAGE 10% T 2.6% C gels at 200 V for 45 min and
electrophoretically transferred to nitrocellulose membrane at 100 V for 45 min (Bio-Rad).
Gelatin (3%) in 0.010 M Tris-HCl, pH 8.0, 0.05% Triton X-100, 0.022 M NaCl (TST) was
used to block non-specific binding sites on the nitrocellulose membrane. After three 15 min
washes with TST the membrane was incubated with anti-MMP-8 antibody (1:1000 dilution
in TST) for 10 h. Polyclonal rabbit anti-human MMP-8 was kindly donated by Dr. Jürgen
Michaelis (Department of Pathology, Christchurch Medical School, Christchurch, New
Zealand) (Michaelis et al., 1990). After three 15 min washes with TST the membrane was
incubated with alkaline phosphatase-conjugated goat-anti-rabbit IgG (1:1000 diluation in
TST; Sigma, St. Louis, Mo.) for 1 h. After washing with TST for 15 min with 0.010 M Tris-
HCl, pH 8.0, 0.022 M NaCl, the immunoblots were visualized by addition of nitro blue
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) diluted to N-N-
dimethyl-formamide (Sigma) in 0.020 M Tris-HCl – 0.005 M MgCl2 – 0.150 M NaCl, pH
9.5. All incubations were performed at 22°C. The secondary antibody did not react with the
bands detected by Western blotting. Positive controls for neutrophil MMP-8 and
mesenchymal MMP-8 were produced as described in detail elsewhere (Salo et al., 1995;
Sorsa et al., 1985).
All values represent mean±SEM. For comparison between groups, t-test was used for
normally distributed variables and Wilcoxon signed rank test for skewed variables.
6.4 GENERAL METHODS
Isolation of collagen
The type I collagen needed for enzyme assays was isolated by sequential salt precipitations
at neutral and acidic pH. The collagen was dialysed extensively against 0.05 M acetic acid,
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and lyophilised. A substrate solution was prepared by careful dissolution of a weighed
amount of the dry protein. When the concentrations were not obtained by direct
measurement, the preparate was hydrolysed and assayed for hydroxyproline by a
modification of the method described by Kivirikko & Prockop (Kivirikko et al., 1967).
Before use, the identity of the protein bands was checked by cutting the protein with human
leukocyte collagenase to produce typical cleavage patterns of type I collagen.
Isolation of leukocytes for cell stimulation studies and immunocytochemistry (II)
Human polymorphonuclear leukocytes were isolated from fresh blood of voluntary healthy
persons. Two 10-mL EDTA-blood samples were centrifuged at 200 g for 5 minutes. The
harvested cells were washed twice to reduce the number of thrombocytes. After washes, 1
mL of the buffy coat layer transferred into a test tube containing 1 mL of 2%(w/v) Dextran
T500 – 0.15 M NaCl (AP Biotech, Sweden). The cell suspension was then carefully drawn
into a syringe, and left at 25˚C for 30 minutes to sediment. The leukocyte-rich layer was
then injected into a centrifuge tube, harvested at 500 g x 10 minutes, and suspended in 0.2
mL of PBS.
The remaining erythrocytes were lysed by a hypotonic shock – a ten-fold volume of ice-cold
distilled water was added, followed by ice-cold 0.3 M NaCl at 25 seconds to restore the
conditions. The cells were harvested by centrifugation (250 g x 5 minutes), and suspended in
0.2 mL of PBS.
The cell suspension was pipetted on 1.0 mL of Ficoll-Paque or Lymphoprep solution (1077
g/L), and centrifuged at 250 g for 15 minutes. The supernatant was discarded, and the cell
pellet suspended in PBS. Serial dilutions of the suspension were smeared on an object slide,
and stained with hematoxylin to check purity of the preparate.
When prepared for a stimulation experiment, the cells were counted in a Burker chamber.
The viability of the cells was tested by exclusion of Trypan Blue, and preparates with less
than 85% viable cells were discarded.
For immunocytochemistry, the cells were pipetted at four 10-fold dilutions in the sample
compartment of a cytocentrifuge (Shandon Elliot). The cells were pelleted on object slides
by running at speed 55 for 7 minutes. The slides were stained with hematoxylin, and the best
concentration of cells chosen for the experiments.
Isolation of leukocytes for purification of leukocyte collagenase
For medium scale purification of leukocyte collagenase, The Finnish Red Cross kindly
provided 4 to 5 liters batches of buffy coat. The buffy coat was mixed with an equal volume
of 2% Dextran T500 – 0.15 M NaCl, and poured into a separation funnel. The red blood
cells were sedimented at 25˚C, until a clear boundary had formed between the leukocyte-rich
layer and the erythrocyte-rich layer. The erythrocytes were then drained to waste, followed
by collection of the leukocyte-rich layer into centrifuge cans.
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The cells were harvested at 100 g x 25 minutes, and suspended in PBS. A ten-fold volume of
ice-cold distilled water was added, mixing the suspension, and the osmolarity restored by
adding 0.3 M NaCl at 30-45 seconds, with continuous mixing. The cells were harvested
again, by centrifugation at 100 g for 25 minutes, and stored at –80˚C until used.
Stimulation of polymorphonuclear leukocytes in suspension
Polymorphonuclear leukocytes were adjusted to 104 cells per ml before adding 50 ng/ml of
phorbol myristic acetate. After 15 minutes at 25˚C, the cells were collected by centrifugation
and the supernatant used as a source of collagenase.
Measuring collagenase activity
Collagenase activity was measured by incubating the sample with Type I collagen at 1.0
micromoles/liter at 25˚C. The incubation was terminated by adding non-reducing SDS-
PAGE sample buffer and heating the sample in a boiling water bath for 5 minutes. The
degradation products were then separated by SDS-PAGE and the gel scanned. The ratio of
the peak area of ¾-cleavage fragments and peak area of intact collagen α1 and α2 bands
were used to calculate the per cent value of the peak areas. The activity was then expressed
as per cent collagen degraded per hour.
Tetracycline inhibition experiments
Cleavage of alpha-1-antitrypsin by MMP-8 was inhibited by mixing the sample with a
tetracycline solution and pre-incubating for 30 minutes at room temperature. The
collagenase activity of the sample was then measured as described above.
Writing a user interface for the microplate reader
A microplate reader (Multiskan, Labsystems, Finland) was connected to a portable PC
(Chicony Ltd, Taiwan) via the RS-2322 port. The software needed to communicate with the
microplate reader was written in the laboratory, using the QBASIC programming language
and the instruction manual of the apparatus. The microplate reader was used for synthetic
peptide-p-nitroanilide based peptidase assays, the Bradford total protein assay, and a
modification of Neuman & Logan hydroxyproline assay.
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Measuring Cathepsin G and chymotrypsin-like proteinases
A synthetic 4-nitroanilide peptide substrate (succinyl-Ala-Ala-Pro-Phe-4-nitroanilide) was
used to measure Cathepsin G activity. The peptide hydrolases with chymotrypsin-like
specificity cuts the substrate molecule on the carboxyterminal side of phenylalanine,
releasing 4-nitroaniline. The molar amount of 4-nitroaniline was estimated by constructing a
standard curve for 4-nitroaniline in the assay buffer, using a 0.100 mL and 0.200 mL
reaction volumes on a microplate. The absorbance values were then read on a microplate
reader using a 405-nm filter. The activity of cathepsin G was measured in a 5-point fixed
time assay, and expressed as nanomoles per liter substrate cleaved per second. (Del Mar et
al., 1980)
Total protein assay
Protein concentration in protein solutions was measured by a modification of the dye-
binding method of Bradford (Bradford 1976). The coomassie brilliant blue G-250 solution
was prepared in the laboratory, and stored at +4˚C. A volume of 0.040 mL of the dye reagent
was added to 0.160 mL of a sample. The color formed was measured at 620 nm. A series of
standard protein dilutions prepared from bovine serum albumin was used on each plate
measured.
Extraction of metalloproteinases from human rheumatoid synovium
The subsynovial tissue samples obtained from patients with rheumatoid arthritis were
weighed, and snap-frozen in liquid nitrogen. The samples were stored at –80˚C until used for
extraction.
On thawing, the samples were homogenised in 5-10 volumes of 0.05 M Tris-HCl – 1.0 M
KCl, pH 7.50. The insoluble material and cell debris was removed by ultracentrifugation at
100,000 g for 30 minutes at +4˚C. The supernatants were stored frozen until analysed.
Immunohistochemistry
• sample preparation – fixation and sectioning procedures
• avidin-biotin-horseradish peroxidase ABC-method
• alkaline phosphatase detection method
• counterstaining
• morphometry
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Electrophoresis under denaturing conditions
A MiniProtean II apparatus was used in all experiments. The SDS-PAGE was run using
0.1% (w/v) SDS in an Ornstein-Davis buffer system.
Quantitation of electrophoresis gels by laser densitometry
For most of the work described in the publications, a laser densitometer scanning at 660 nm
(LKB, Sweden) was used. The data were exported to AXXIOM chromatography program
for peak integration and subsequent calculations.
Protein Blotting
To detect the metalloproteinases by immunological methods, the proteins were I onto
nitrocellulose of PVDF membranes using a Mini Protean II blotting apparatus (BioRad,
Richmond, CA).
To transfer proteins from non-denaturing gels to blotting membranes, a brief soak in SDS-
solution (Delcuve & Davie) was used.
Immunohistochemical methods
A. Fixation methods
For most samples in study III, the immunohistochemical samples were frozen sections that
were fixed with for 3 minutes in cold acetone. As an exception, a paraffin embedded control
sample from a mammary carcinoma patient (kindly provided by professor Jarkko Hietanen)
was used as a positive control for MMP-13.
B. Antibodies
The antibodies used to detect MMP-13 and MMP-1 in study III were:
• polyclonal rabbit-anti-MMP-13 kindly provided by Dr. Vera Knäuper
• polyclonal rabbit-anti-MMP-13 kindly provided by Dr. C. Lopéz Otìn
• polyclonal rabbit-anti-MMP-1 kindly provided by Dr. LM Golub.
C. Detection methods
The samples were cut to 6-micrometer thick sections and fixed with acetone for 5 minutes at
4˚C. The avidin-biotin complex technique of Hsu et al. was performed using a VectaStain
Elite ABC Rabbit Kit (Vector, Burlingame, CA).
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Endogenous peroxidase was inhibited with 0.3% hydrogen peroxide in methanol for 30
minutes. The samples were incubated serially with 1) normal goat serum for 30 minutes, 2)
rabbit-anti-human MMP-13 (diluted 1:500) for 60 minutes, 3) biotinylated goat-anti-rabbit
IgG (diluted 1:133) for 30 minutes, 4) ABC (diluted 1:100) for 30 minutes, and 5) 3,3’-
diaminobenzidine tetrahydrochloride (DAB) – 0.006% hydrogen peroxide in 0.05 M Tris-
0.15 M NaCl, pH 7.4 (TBS). Finally, the sections were washed in tap water, dehydrated,
cleared and mounted. One of the consecutive sections of each patient was counterstained
with Harris’s hematoxylin solution before the dehydration step.
D. Double staining methods
To detect two antigens in a single section, two detection systems, were used in succession.
The avidin-biotin complex method of Hsu was used to detect immunoreactive MMP-13 and
alkaline phosphatase-anti-alkaline phosphatase (APAAP) method was used to detect the
macrophage marker CD68. First, 5 micrometer thick frozen sections were stained using
polyclonal rabbit-anti-rhMMP-13, following the protocol for the ABC staining method up to
the step where the section were rinsed in running tap water. Second the slides were washed
with 0.05 M Tris-0.15 M NaCl, pH 7.4 (TBS) buffer and incubated at 25˚C in 1) normal
rabbit serum (1:50) for 1 hour, 2) mouse-anti-human CD68 IgG (dilution 1:50) for 1 hour, 3)
rabbit-anti-mouse IgG solution (1:25) for 1 hour, and 4) APAAP solution (dilution 1:25) for
1 hour. The antibodies bound to the tissue sections were then visualised by adding bromo-
chloro-indoyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) and incubating at 25˚C
for 10 minutes covered from light. The endogenous alkaline phosphatase was inhibited by
including 0.003 M levamisole. Finally, the sections were dehydrated, cleared in xylene and
mounted.
E. Immunohistochemical staining controls
The specificity of the immunoreaction was tested by including control sections that were
stained with preabsorbed antibody as decribed by van Noorden (van Noorden 1986). In the
procedure, the most dilute antibody concentration still giving reproducible staining of MMP-
13 for the tissue was determined, and this working dilution (1:1000) was incubated with 0.1
nanomoles of the antigen overnight at +4˚C. This antibody solution, presaturated with the
antigen, was used instead of the untreated primary antibody.
Mathematical methods
• estimating the net charge of polypeptides from amino acid composition
Using a spreadsheet program, the theoretical net charges for the proteins were calculated as
a function of pH. The procedure consisted of three steps:
1. downloading the sequence from Swiss-Prot or Uni-Prot protein data bank
2. calculating the amino acid composition
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3. calculating the theoretical net charge using the frequency and Ka coefficient of
each amino acid
The results were plotted on a charge vs. pH scale for each protein to be separated from each
other. The plot was then read to identify pH range at which the difference in net charge
would be largest.
Statistical methods
The statistical calculations were performed using BMDP 7.01 and, in most cases, the small
number patients and the data distribution made us choose the Mann-Whitney U test for
unpaired groups.
6.5 METHODS (IV)
The study protocol was approved by the Helsinki Health Centre Research Coordination
Committee. Because the investigation involved only the review of patient records obtained
during the course of medical care, no patient consent was required.
Data were collected from the dental records of 100 consecutive patients aged 40 years or
older, who had been referred to the University Dental Clinic, Health Centre of Helsinki, for
periodontal treatment during 2004-2005. Each patient was assigned an encrypted code
linking the research data to the patient documents. Subjects with more than 14 teeth were
included in the analysis. The patients who did not use statins formed the control group.
We extracted the following data from the patient records: age, gender, smoking status, and
use of statin medication. The records were checked for medications, diabetes, rheumatoid
diseases, smoking, and indicators of periodontal health.
For all teeth, we collected periodontal Probing Pocket Depth (PPD) values, measured to the
nearest millimetre, from mesiobuccal, midbuccal, distobuccal, distolingual, midlingual, and
mesiolingual surfaces using a WHO periodontal probe (Ainamo et al., 1982; Armitage
2004a; 2004b). For a full dentition of 28 teeth, this yields 168 measurements. A gingival
sulcus is considered physiological when PPD is less than 4 mm. The number of sites with
moderate periodontitis (PPD at least 4 mm and less than 6 mm, modPPD) and advanced
periodontitis (PPD 6 mm or deeper, advPPD) were recorded separately. For a dentition of 28
teeth, both of these indicators yield a maximum value of 168.
A novel clinical index, Periodontal Inflammatory Burden Index or PIBI, was derived from
the PPD values. The index is calculated by adding the number of periodontal sites indicating
moderate periodontitis (NmodPPD) to the weighted number of periodontal sites indicating
advanced periodontitis (NadvPPD).
(1) NmodPPD = number of sites with moderate periodontitis
(2) NadvPPD = number of sites with advanced periodontitis
(3) PIBI = ∑ (NmodPPD + 2 NadvPPD)
If all measurement sites are advPPD in a 28-tooth dentition, PIBI can reach a maximum
value of 336.
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Statistical analysis
Student’s t-test was used to compare the means of the outcome variables following normal
distribution. Kolmogorov-Smirnov test was used to estimate normality of the distribution,
and Levene’s test the equality of variances. The distribution-free Mann-Whitney U-test was
applied to compare the medians when the values were not normally distributed (Campbell &
Gardner 1988). Statistical calculations were performed using SPSS versio 13.0 software
(SPSS Inc., Chicago, Illinois) when appropriate. The results are given as mean, standard
error (SE), and the number of subjects in the group, unless otherwise indicated. The 95%
confidence intervals and exact two-tailed p-values are given for each comparison.
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7. RESULTS
7.1. Results (I)
Immunohistochemistry
Immunohistochemistry revealed that PMNs on PB and SF in ReA and RA had intense and
consistent granular cytoplasmic staining for cathepsin G, elastase (Study I, Figure 1), α1-
ACT and α1-PI. Individual cells varied only slightly in staining intensity. There was no
difference in the intensity of staining between corresponding PB and SF PMNs (not shown).
In contrast to PB PMNs, monocytes in PB showed heterogeneity in staining with more than
half of all cells being negative in any staining for the above mentioned proteinases and their
inhibitors (Study I, Fig.2). Only a few monocytes attained the intensity of PMN staining.
Furthermore, positively stained monocytes were more rare in SF than in PB.
Bone marrow smears from healthy controls showed strong positive stsaining for cathepsin G
(Study I, Fig. 3) and elastase in promyelocytes, metamyelocytes as well as in neutrophils
and some monocytes, plasma cells, lymphocytes megakaryocytes and erythroblasts being
negative.
Activities of leukocyte cathepsin G and elastase
Both cathepsin G and elastase activities were measured from RA SF (n=10) and were found
to be 16.4 ± 6.2 IU/l and 6.51 ± 1.8 IU/l, respectively. Both values differed significantly
from the relatively low activity levels in PB in RA: 0.53 ± 0.4 IU/l (p < 0.05) and 1.22 ±
0.58 IU/l (p < 0.05), respectively. The trend was similar in ReA (n=8), although the
differences did not reach significance; 11.4 ± 9.2 vs 4.8 ± 1.7 for cathepsin G and 5.1 ± 2.8
vs 2.3 ± 2.2 for elastase.
There was a significant covariation of cathepsin G and elastase in both ReA and RA SF,
with the correlation coefficient being 0.78 (p<0.05) in ReA and 0.84 (p<0.05) in RA.
Highly cellular SF (SF-Leuk) in ReA had higher activities of both cathepsin G (r = 0.63, p =
0.08) and elastase (r = 0.77, p < 0.05), whereas this association was weaker in RA (the
corresponding correlation coefficients were 0.39 and 0.37, respectively). ReA patient no. 14,
who presented with a very active inflammation (Study I, Table I), showed the highest levels
of cathepsin G and elastase in booth SF and PB.
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Immunoreactive serine proteinases and their endogenous inhibitors
Twelve samples were selected from ReA and RA SF so that both samples with measurable
and nil values for enzyme activities were included. All samples contained immunoreactive
cathepsin G (Study I, Fig. 4) and elastase (not shown). All samples also contained
endogenous serine proteinase inhibitors (serpins) α1-PI and α1-ACT.
7.2. Results (II)
Immunohistochemistry results. All the synovial samples used in this study showed
immunoreactivity to anti-MMP-13. Staining for MMP-13 was observed in synovial lining,
endothelial, and stromal cells (Study II, Figure 1). Double labeling for MMP-13 and CD68
confirmed that MMP-13 was expressed in both synovial fibroblasts and monocyte
macrophages, as well as in both A and B synoviocytes (Study II, Figures 2A and B). In
addition, in RA, accumulations of mononuclear inflammatory cells, apparently lymphocytes,
in perivascular and sublining areas were negative for both MMP-13 and CD68 (data not
shown).
The results of morphometric assessments are presented in Study II, Table 2. Although the
majority of the lining, synovial stromal, and endothelial cells from both RA and OA patients
were found to express MMP-13, the ratio of MMP-13-positive synovial lining and stromal
cells was significantly higher in RA than in OA patients (for lining cells P = 0.0262; for
stromal cells P = 0.0027). The ratio of MMP-13-positive endothelial cells in RA and OA
patients did not differ statistically significantly (P = 0.3491). The control samples from
patients with other joint derangements were excluded from statistical comparison due to the
small number of cases.
Cytospin preparations of neutrophils (known to be MMP-8-positive) did not stain with anti-
MMP-13. Positive staining for MMP-13 was found in the ductal epithelium of the
mammalian carcinoma specimens (not shown). Absorption control with purified
recombinant MMP-13 abolished staining from strongly positive cells, leaving a light brown
background. The antigen to antibody ratio in the absorption test was calculated to give at
least a 20-fold antigen excess over the binding sites. Detection of synovial tissue extract
collagenases blotted onto nitrocellulose. Regular SDS-PAGE did not allow unequivocal
separation of the 2 MMPs (data not shown). After calculation of the isoelectric points, 2
buffer systems were chosen for separation, both with a reduction step added in sample
preparation. At low pH, where pro-MMP-1, MMP-1, pro-MMP-13, and MMP-13, according
to calculations, have different charges, the recovery of protein on nitrocellulose was low. In
contrast, at pH 9.5, protein recovery was better and a clear separation of MMP-1 and MMP-
13 could be achieved: the relative mobility for the fastest-migrating MMP-1 and MMP-13
bands was 0.4 and 0.56, respectively (Study II, Figure 3). A control sample of 300 ng of
MMP-1 blotted from a high-pH native gel was not detected by anti-MMP-13 antibody (data
not shown).
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Calculated charge of proteins before electrophoresis
In study II, we calculated predicted charge values for MMP-1 and MMP-13 to help in the
selection of the electrophoretic method.
During the electrophoretic transfer, the proteins move in the mobile phase because they
carry a net charge. In SDS-PAGE the differences in the charges are overcome by adding
excess of an anionic detergent, sodium dodecyl sulfate, so that the main property affecting
the electrophoretic mobility is the molecular size of the proteins.
It is possible to estimate the predicted charge of a protein, but this is based on several
assumptions:  1) the dissociation constants (Ka) of the amino acid side chains respond to
those estimated 2) there are no conformational constraints so the side chains are all exposed
3) there are no other charged groups on the protein.
The net charge of a protein molecule is determined by the charged side chains of the
molecule. Several of these interact with each other or are buried within the protein teriary
structure.
At the present, the charge calculations are available as charge plots or isoelectric plots in
molecular biology database providers and can be considered a standard tool. The change of
charge of the protein on the removal of propeptide is presented in Figure 6. The net charge is
calculated using two equations easily derived from the equations for the dissociation
constants. The net charge sum is calculated from the equations 1 and 2 for the positively
charged and negatively chaged groups, respectively:
(1) Σ zi ni Kai ([H+] + Kai)-1
(2) Σ zi ni [H+] ([H+] + Kai)-1
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Figure 7 Charge-pH relationship of pro- and active forms of collagenases 1 to -3
 The differential change in the calculated charge can be seen in Figure 7 and 8. The largest
change in pH range 4-5. The shoulder in the differential curve represents the effect of
histidine (H) residues on the charge.
Inhibition characteristics of the recombinant MMP-13. Clodronate, pamidronate, and D-
penicillamine were assessed over a range of concentrations that can be reached with regular
treatment and/or that have been shown to inhibit other collagenases (Golub et al., 1984;
Suomalainen et al., 1992; Teronen et al., 1995). Activity was measured using a soluble type
II collagen assay (Study II, Figure 4).
Clodronate, pamidronate, and D-penicillamine did not inhibit recombinant MMP-13 (Study
II, Figure 5). Doxycycline had inhibitory potential starting at approximately 200 µM, but the
50% inhibition concentration (IC50) values were not yet reached at 500 µM (Study II, Figure
5). This differs from the IC50 values for MMP-8 (26 µM) and for MMP-1 (280µM)
(Suomalainen et al., 1992).
-20
-10
0
10
20
30
40
50
60
70
80
024681012
proMMP1
MMP1
proMMP8
MMP8
proMMP13
MMP13
53
0
0,5
1
1,5
2
2,5
3
3,5
4
4,5
0 2 4 6 8 10 12
MMP1
MMP8
MMP13
Figure 8 Charge-pH differential curves of collagenases 1 to 3.
Figure 9 Charge-pH differential curves of MMP-2 and MMP-9
0
1
2
3
4
5
6
7
0 2 4 6 8 10 12
MMP2
MMP9
54
7.3. Results (III)
All patients completed their 3-month treatment so that there were no drop-outs. Significant
reductions in joint score index (tender joints) were seen at 6 and 12 weeks (16±2 vs 11±2,
P<0.01; 16±2 vs 8±1, P<0.01). However, Hb, CRP, ESR or changes in functional class were
not seen during the 3-month-long intervention period. Pain VAS was reduced at 12 weeks
(50±7 vs 34±8, P<0.05). Among the seven PDI variables a significant reduction was seen in
domestic disability at 12 weeks (53±8 vs 42±7, P<0.05) and in vocational behaviour at 12
weeks (23±5 vs 10±4, P<0.001). None of the five CPRS variables changed during the study
period. HAQ scores did not change during the trial.
Quantitative SDS-PAGE electrophoresis scanning of the patients’ saliva samples showed
that collagenase activity was significantly reduced at 12 weeks [15±2 vs 10±2 (% type I
collagen degraded), P<0.01 (Study III, Figure 1), one patient’s samples. Concomitant
Western blots (Study III, Figure 2, two patients’ samples) showed intact MMP-8 enzyme
(75–80 kDa band) and a smaller 40–55 kDa band. The former moved together with a
purified neutrophil MMP-8 and the latter with the mesenchymal MMP-8. Fibroblast-type
MMP-1 collagenase was not found in RA saliva. All patients completed the study. Patient 1,
however, contracted an oral candidiasis 3 weeks prior to the final examination. In addition,
minor side effects were noted such as gastric discomfort including loose stools (patient 4)
and vaginal fungal infection (patient 7), which did not lead to interruptions in the
medication.
7.4. Results (IV)
Patient characteristics
The demographic data of study subjects are presented in Study IV, Table 1. Of the 100
consecutive patients referred to the clinic for periodontal treatment, three did not fulfil the
inclusion criteria of having at least 50% of the dentition remaining. Of the eligible subjects
(n=97), 44 were women. The mean age of all study subjects was 53 years (range 42-69
years). The mean age in the control group was lower than in the statin group (Study IV,
Table 1).
The percentage of smokers was greater in the statin group (28.6%) than in the control group
(18.4%). Diabetes was more frequent in the statin users (28.6%) than in the controls (3.9%).
The percentage of patients with rheumatic disease was similar in both groups. The mean
number of remaining teeth in the statin group was 24.3 (SE 0.7) and in the control group
26.1 (SE 0.4); the difference of means was 1.8 (95% CI 0.3-3.4; p=0.02). Assuming full
dentition to be 28 teeth, the average remaining dentition in the statin group and control
group was 86% and 93%, respectively. All subjects had poor oral hygiene, evident as visible
dental plaque and gingival bleeding on probing.
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Twenty-one subjects were on statin medication: 11 used atorvastatin, 7 simvastatin, 2
fluvastatin, and 1 rosuvastatin. All patients in the statin group were receiving a conventional
low-dose statin therapy.
Periodontal inflammatory injury
Numbers of periodontal pockets in subjects with and without statin medication are shown in
Study IV, Figure 1 (means/medians and 95% CIs). In the control group, the mean number of
at least 4 mm deep periodontal pockets was 79.1 (SE 3.7; n=76) (Study IV, Figure 1A). In
the statin group, the corresponding number was 50.1 (SE 7.0; n=21), being 37% lower than
in the control group. The difference of means was 29.0 (95% CI 12.9-45.0; p=0.00043)
(Study IV, Table 2).
Data were analysed separately for moderate periodontitis and advanced periodontitis. In the
control group, mean NmodPPD was 50.7 (SE 2.5; n=76) (Study IV, Figure 1B). In the statin
group, mean NmodPPD was 36.0 (SE 5.0; n=21), being 29% lower than in the control
group. The difference of means was 14.7 (95% CI 3.2-26.2; p=0.0087) (Study IV, Table 2).
Advanced periodontal inflammatory injury was measured as the number of periodontal
pockets at least 6 mm deep. In the control group, mean NadvPPD was 28.4 (SE 2.6; n=76).
In the statin group the mean was 14.2 (SE 3.8; n=21), being 50% lower than in the control
group. The difference of means was 14.2 (95% CI 4.9-23.5; p=0.0034). The NadvPPD data
indicating advanced periodontitis did not follow normal distribution. We therefore used the
distribution-free Mann-Whitney U-test to compare the population medians. The median was
20 for the control group and 11 for the statin group. Calculated as described elsewhere
(Campbell & Gardner 1988), the estimated difference in population medians was 11 and the
approximate 95% CI for the difference in population medians 4-20 (p=0.0010) (Study IV,
Figure 1C, Study IV, Table 2).
The Periodontal Inflammatory Burden Index (PIBI) combines and unifies data on PPD.
Mean PIBI was 107.6 (SE 5.8; n=76) in the control group and 64.3 (SE 10.0; n=21) in the
statin group (Study IV, Figure 1D). The difference of the means was 43.1 (95% CI 19.5-
66.7; p=0.00069). The PIBI was 40% smaller in the statin group than in the controls.
The comparison of PIBI in subjects using simvastatin and atorvastatin is presented in Study
IV, Figure 2. Subjects on simvastatin as well as those on atorvastatin showed 40% lower
mean PIBI values than subjects in the control group. We observed no difference in PIBI
between subjects on simvastatin or atorvastatin. The small number of subjects on fluvastatin
or rosuvastatin did not allow their inclusion in the comparison.
To describe local inflammation and average intensity of inflammation per tooth, we divided
the PPD values and PIBI by the number of teeth. The tooth-adjusted means of all of these
clinical periodontal inflammatory signs were lower in the statin group than in the control
group (Study IV, Table 2).
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8. DISCUSSION
In this section, the results studies I to IV are discussed, followed by a more general and
compact discussion on the original studies.
8.1 Discussion (I)
Under usual circumstances PMNs play a protective role by being rapidly recruited to sites of
bacterial invasion in pyogenic infections. This is based on their ability to leave the
circulation, to migrate along chemotactic gradients, to become activated and to phagocytose
and kill bacteria (Henson et al., 1988). The combined proteolytic and oxidative tissue
destructive potential of PMNs (Matrisian 1990; Jeffrey 1986) may lead to complications, if
the activation is inadvertent or uncontrolled. This type of situation has been suggested to
prevail in RA (Zvaifler 1973). Rheumatoid synovitis tissue is a site of intense
immunoglobulin production. Some of the immunoglobulin has anti-immunoglobulin or
rheumatoid factor activity (Heimer & Levine 1966). This leads to a local formation of IgG-
RF complexes that are rapidly phagocytosed by synovial fluid neutrophils. During the
process of phagocytosis some of the granular content of PMNs is released into extracellular
milieu and may cause tissue injury and inflammation (Hirsch & Cohn 1960). RA has,
according to the phagocyte hypothesis originally formulated by Daniel McCarty (Hollander
et al., 1962), been regarded as an extravascular, intra-articular immune complex disease.
Although PMNs also in ReA are engaged in phagocytosis, as is evidenced by the
intracytoplasmic presence of bacterial antigens derived from the initial, triggering infectious
agent (Schumacher et al., 1986; Keat et al., 1987; Granfors et al., 1989; 1990), it is not
known whether this is associated with an intra-articular release of PMN proteinases into SF
in ReA. However, it is not clear whether bacterial antigen containing PMNs are formed in
situ or are recruited from the circulation after phagocytosis elsewhere- We believe that they
are formed in situ because it would be unlikely that immunoreactivity would be retained for
long after phagocytosis. Increased enzyme activities in SF in ReA also testify for activation
(and concomitant enzyme release) in loco.
Immunohistochemical staining results and synovial fluid leukocyte differential counts
suggest PMN as the main cellular source of SF cathepsin G or elastase (see also Fig. 3). This
fraction of serine proteinase containing mononuclear phagocytes was low in SF compared to
parallel PB samples, which might be due to depletion by local release and lack of synthesis
de novo. This is in accordance with earlier studies, which have demonstrated that 1) in
contrast to PB monocytes, tissue macrophages are negative for cathepsin G and elastase
(Senior et al., 1982); 2) monocytes loose peroxidase, cathepsin G and elastase containing
granules upon differentiation to macrophages in vitro (Kargi et al., 1990); 3) cathepsin G
and elastase are synthesized only during the promonocyte (and promyelocyte) stages
(Hanson et al., 1990; Takahashi et al., 1988). Therefore, SF PMNs form an easily
recognizable pool of cathepsin G and elastase, whereas monocytes and mature tissue
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macrophages probably only make a minor contribution, because they are few and/or weakly
staining (Senior et al., 1982). A good correlation between SF leukocyte counts and serine
proteinases in ReA further testify for local release from neutrophil as the likely mechanism
responsible for the present observations. Positive correlation between cathepsin G and
elastase activities fits well with the observations on their common subcellular localization in
peroxidase containing azurophilic granules in PMNs (and to a smaller degree in monocytes).
Furthermore, the exaggerated inflammatory responsiveness/PMN chemotaxis found in
HLA-B27 positive individuals (Repo et al., 1984) is also in keeping with this reasoning.
It was noteworthy, that in accordance with neutrophil collagenase MMP-8 (Konttinen et al.,
1991), there was no significant depletion of the intracellular PMN cathepsin G or elastase
stores, at least not to such an extent that it would have been discernible in staining. As
discussed in detail elsewhere, this may be due to partial release, release in secluded sites
(such as from PMNs attached to the surface of articular cartilage); or release upon cell death
(Weissman et al., 1979).
All SF samples seem to contain immunoreactive cathepsin G and elastase; however, not all
samples contained measurable enzyme activities. This might in part be due to the local
presence of specific inhibitors, among which α1-ACT is particularly effective against
cathepsin G and α1-PI against elastase (Chandra et al., 1983; Travis & Salvesen 1983).
Interestingly, PMNs were found to contain also these serine proteinase inhibitors, which also
form about 10% of all plasma proteins. Semiquantitative evaluation of the SF inhibitor
content by dot-blotting indicates that serine proteinase inhibitors are found to a crudely
similar extent in ReA and RA.
In contrast to RA, which usually leads to typical articular erosions, patients with ReA
usually recover without permanent joint damage (Konttinen et al., 1988). According to the
present study, this does not seem to be due to lack of local PMN responses. Neither does it
seem to be due to total inhibition of the enzyme activities by endogenous inhibitors, because
the enzyme and inhibitor levels were similar in ReA and RA. It seems more likely, as we
have suggested in an earlier study (Konttinen et al., 1986), that the favourable clinical course
of ReA compared to RA is due to the fact that the brisk and maybe even exaggerated initial
PMN response is, during course of time, down-regulated. It was therefore of some interest,
that one ReA patient, who developed a chronic and severe inflammation requiring both
intra-articular corticosteroids and methotrexate treatment, showed the highest levels of both
SF and PB cathepsin G and elastase, thus suggesting chronicity in ReA leads to a similar
pathway in joint destruction as seen in RA joints (Konttinen et al., 1988). The relatively
benign usual course of the disease might be due to the disappearance of the driving stimulus,
perhaps the bacterial antigens as speculated above. This would be in line with our recent
results on the beneficial clinical effects of tetracyclines on the course of Chlamydia-induced
ReA (Lauhio et al., 1991). It also remains to be seen to what extent these findings are
explained by the non-antimicrobial effects of tetracyclines, such as their anti-collagenolytic
effects (Lauhio et al., 1992; 1994; 1995; Kloppenburg et al., 1994) and their protective effect
on α1-PI proteinase inhibitor shield (Sorsa et al., 1993).
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8.2 Discussion (II)
In the original work by Freije and coworkers (Freije et al., 1994), MMP-13 mRNA was
found in breast carcinomas, but not in normal human tissues. However, articular cartilage
was not included in their normal tissue panel. Later, Flannery and Sandy reported MMP-13
mRNA expression in chondrocytes (Flannery & Sandy 1995), a finding later confirmed by
Mitchell et al (Mitchell et al., 1996) and by Reboul et al (Reboul et al., 1996). Reboul and
coworkers did not find MMP-13 mRNA in interleukin-1β-stimulated synoviocyte cultures or
in 1 OA synovial tissue sample. In light of the data reported by Reboul et al, the present data
and those recently published by other investigators (Wernicke et al., 1996), it is possible that
MMP-1 and MMP-13 are differently regulated under conditions used in synoviocyte
cultures. Alternatively, in vitro cell cultures do not reproduce the conditions that prevail in
the synovial lining and stroma in vivo. The results presented in this paper are in clear
accordance with those reported by Wernicke et al, who cloned MMP-13 from an RA
synovial sample and demonstrated expression of its mRNA in RA and OA synovial tissue,
but did not find it in several normal human tissues (Wernicke et al., 1996). Our results
demonstrate protein level expression of MMP-13 in RA and OA synovium. MMP-13 seems
thus to be specifically expressed in synovial tissue, which makes it an enzyme of potential
pathogenetic importance in the arthritides.
The combination of high tensile strength provided by type II collagen and high swelling
pressure of the proteoglycan matrix is important for the biomechanical function of cartilage
(Brandt & Mankin 1993; Poole 1993). Different strategies have been used in various
attempts to overcome the poor inherent healing capacity of articular cartilage: heterologous
chondrocytes, periosteum, perichondrium, and osteochondral grafts, and, more recently,
autologous chondrocytes (Brittberg et al., 1994) have been transplanted to treat focal
articular cartilage defects. Because of the importance of type II collagen to the
biomechanical properties of the cartilage and the poor inherent healing capacity of the tissue,
the initial and specific cleavage of type II collagen must be a highly regulated event.
Collagenases of the MMP family are the only mammalian enzymes, which are able to cleave
the α1(II) triple helix at the 775Gly-776Leu peptide bond (Krane 1993). Hitherto, only MMP-1
and MMP-8 have been considered to be responsible for the degradation of type II collagen.
MMP-8, which cleaves type I collagen faster than type II collagen, can be found in synovial
fluid neutrophils (Harris et al., 1969; Konttinen et al., 1991).
The rheumatoid changes are characterized by development of peripheral erosions associated
with fibroblast- and macrophage-like cells at the advancing edge of the pannus (Shiozawa et
al., 1983). These cells have been suggested to contain fibroblast-type collagenase 1 (MMP-
1) (Evanson et al., 1967; Dayer et al., 1976), which, however, is not particularly effective
against monomeric type II collagen (Konttinen et al., 1991; Welgus et al., 1981; Docherty &
Murphy 1990). Therefore, the occurrence of a third type of collagenase, collagenase
3/MMP-13, in synovial tissue in both RA and OA is of particular interest. MMP-13 was
observed in fibroblast- and macrophage-like cells both in the synovial stroma and the lining.
According to recent data, MMP-13 differs from MMP-1 in that it cleaves type II collagen
more efficiently than other fibrillar collagens (Knäuper et al., 1996). In addition, MMP-13 is
active against aggrecan, the major proteoglycan of the hyaline articular cartilage (Fosang et
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al., 1996). Based on its substrate profile against the 2 major components of the hyaline
articular cartilage and its now-demonstrated presence in synovial membrane, we suggest that
MMP-13 may represent a particularly significant mediator of tissue destruction in the
arthritides.
Our immunohistochemical findings of the presence of MMP-13 in RA and OA synovial
membranes were confirmed by demonstrating MMP-13 in synovial tissue extracts. Notably,
no cartilage was included in our samples. Electrophoretic separation in native gels was
efficiently used to separate collagenases that displayed similar apparent molecular weights
in SDS-PAGE. Estimates of charge and isoelectric points are naturally only apparent, since
the calculations cannot include the effects of the conformation or sialic acid content of
MMP-1 and MMP-13. Because of the significant degree of glycosylation of MMP-1 and
MMP-13 (10% and 25%, respectively), possible sialic acid end groups may contribute to the
total charge and mobility of the collagenases. According to our results after electroblotting
of the Ornstein-Davis gels, RA and OA synovial membranes contained both MMP-13 and
MMP-1, which were clearly separated from each other under the conditions used. Separation
in different gel systems also served in the characterization of the MMP-13 and MMP-1
antisera. Selection of the electrophoresis system, therefore, helped to show the presence of
MMP-13 protein in RA and OA synovial tissue. MMPs have a great inherent tissue
destruction potential. Therefore, many MMPs, including MMP-1, are not constitutively
expressed (or only at a low level), but appear first upon appropriate stimulation of the
producer cells with, for example, certain cytokines (Werb & Alexander 1993). Furthermore,
they are usually not stored in the producer cells, but are rapidly secreted after their synthesis
(Werb & Alexander 1993). This type of regulation may be important for the expression of
these enzymes. Therefore, localization of MMP-13-positive cells in the vicinity of
subsynovial lymphocyte infiltrates may reflect increased MMP-13 production due to as-yet-
unidentified inflammatory cytokines produced by the mononuclear cells in rheumatoid
synovitis in situ. Interestingly, there was no difference in MMP-1 and MMP-13 mRNA
expression as analyzed by densitometry from Northern blots standardized for GAPDH
expression (Wernicke et al., 1996). This suggests that, in addition to transcriptional events
mediating the regulation of MMP-13 expression, posttranscriptional events can also be
important. Because of the potential significance of MMPs in joint-destructive events,
inhibitors of MMPs have received extensive interest (see Greenwald et al., 1994). In
particular, drugs already widely used, including tetracyclines (Greenwald et al., 1994) and
bisphosphonates (Teronen et al., 1995), would seem to offer certain practical advantages
over as-yet-unregistered drugs. Tetracyclines and bisphosphonates have been previously
reported to inhibit several members of the MMP superfamily (Greenwald et al., 1994;
Teronen et al., 1995) and may share a common type of mechanism of action. They are now
reported to be relatively ineffective against MMP-13 compared with their potency against
MMP-1 and MMP-8. This type of inhibitory profile, in conjunction with its tissue-specific
localization, substrate profile, and increased expression in RA, may further contribute to the
pathogenetic significance of MMP-13.
In conclusion, our findings suggest that MMP-13 is present in RA synovial tissue and that
MMP-1 and MMP-8 are not the only collagenases involved. In fact, some of the earlier
reports on synovial collagenase may have to be reassessed due to the possible presence of
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collagenase 3/MMP-13 activity. Because of its cellular localization in the fibroblast-like
cells, apparent synovial tissue-specific localization, and substrate specificity, it may play a
major role in local tissue-destructive events. Increased expression in RA may be a reflection
of the catabolic state in the joint and could be explained by the more obvious inflammatory
nature of RA compared with OA. Finally, the relative resistance of MMP-13 to several
known collagenase inhibitors further adds to its pathogenetic significance.
8.3 Discussion (III)
Treatment of RA with minocycline (200 mg/day) for 48 weeks in a series of 219 patients
was found by Tilley and coworkers to be safe and effective for patients with mild-to-
moderate disease (Tilley et al., 1995). At 48 weeks, more patients in the minocycline group
than in the placebo group showed improvement in joint swelling and joint tenderness.
Although no time course was indicated, the minocycline group at the end of the trial showed
greater improvement in hematocrit and ESR. The present clinical findings are compatible
with those recently reported. The lack of response of Hb and acute phase reactants in the
present study may be due to a shorter observation period. The other main conclusion drawn
by Tilley and coworkers was that the mechanisms of action remain to be determined (Tilley
et al., 1995). We have had another starting point in that we, in cooperation with Professor
Lorne M. Golub’s group, have been studying the non-antimicrobial, anti-collagenolytic
properties of tetracyclines and tetracycline derivatives (Golub et al., 1983; Greenwald et al.,
1987; Suomalainen et al., 1992). Doxycycline inhibits “neutrophil” collagenase MMP-8 in
vitro at concentrations (IC50=26 µM) readily attainable by routine treatment, whereas
“fibroblast” collagenase MMP-1 is more resistant (IC50 = 280 µM) (Suomalainen et al.,
1992). In addition, tetracyclines can inhibit the oxidative activation of pro-collagenases
(Lauhio et al., 1992). After stopping the tetracycline treatment in patients with reactive
arthritis, MMP-8 activity (also in saliva) returns back to higher levels, therefore, explaining
the need for long-term tetracycline regimes (Lauhio et al., 1995). Recently, we have
documented a beneficial effect of doxycycline treatment on Chlamydia-triggered reactive
arthritis, which may in part be based on the inhibition of collagenase activity (Lauhio et al.,
1991; 1992; 1994). The beneficial effects of doxycycline treatment on the course of reactive
arthritis can probably not totally be ascribed to its antimicrobial effects in spite of the clear
role of an infection as a trigger for reactive arthritis. On the other hand, the anti-
collagenolytic effects seen during doxycycline treatment of reactive arthritis cannot be
ascribed to drug effects alone, because reactive arthritis has a tendency to heal
spontaneously, so that the clinical symptoms tend to disappear and the acute phase response
to cease. We believe the present results demonstrate that doxycycline exerts an inhibitory
action on collagenase activity levels, not only in vitro (Greenwald et al., 1987) and in
experimental animal models (Greenwald 1994), but also in vivo in RA patients.
Furthermore, this inhibition of collagenase enzymes may in part explain the beneficial
effects of doxycycline treatment in arthritis.
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Because of the relative resistance of fibroblast collagenase MMP-1 to tetracycline inhibition
(Suomalainen et al., 1992), it was concluded that tetracyclines would be effective mainly in
diseases, in which the polymorphonuclear neutrophilic leucocyte (PMN) is the main
mediator cell. This is probably the fact in arthritides characterized by a PMN predominance
in the synovial fluid and, in particular, in RA which has been considered as an extravascular,
intra-articular immune complex disease to PMN-mediated phagocytosis of synovial fluid
immune complexes and regurgitation of proteinases during feeding (Hollander et al., 1965;
Zvaifler 1973). It was earlier believed that MMP-8 is only synthesized during the myelocyte
stage of development of the PMNs and stored in the specific or secondary granules of the
mature PMNs. More recently, “neutrophil” collagenase synthesis has been demonstrated
also in articular chondrocytes (Chubinskaya et al., 1996; Cole et al., 1996) and in TNF-a-
stimulated synovial fibroblasts (Hanemaaijer et al., 1997; Salo et al., 1995). In the two last
mentioned cells, the MMP-8 is less glycosylated and has an apparent molecular weight of
40–55 kDa, which contrasts with the 85–80 kDa molecular weight of the “classic” PMN
enzyme. These new findings seem to widen the spectrum of diseases, in which the anti-
collagenolytic effects of tetracyclines might be of potential usefulness. Interestingly, the
present study demonstrates a significant decrease in the total collagenolytic activity of the
stimulated whole saliva. Doxycycline-mediated collagenase inhibition occurs in vitro in the
presence of physiological concentrations of Ca2+ and Zn2+ in a reversible and non-
competitive manner (Sorsa et al., 1994). Other inhibitory mechanisms have been proposed.
Smith et al. have shown that upon exposure to doxycycline human recombinant MMP-8, is
fragmented to inactive low-molecularweight species (Smith et al., 1994; 1996). However,
our results do not indicate that corresponding fragmentation is associated with decrease in
collagenase activity in vivo. At the same time, Western blotting demonstrates that this total
collagenolytic activity is associated with the presence of both the classic neutrophil
collagenase and of the “mesenchymal” MMP-8. In fact, this is the first study, in which the
mesenchymal MMP-8 isoenzyme has been demonstrated in a body fluid in man.
As this study suggests, the clinical improvement of RA patients during tetracycline
treatment is associated with an inhibition of the collagenases. Due to the enzyme-species-
specific inhibition of different collagenase isoforms, it seems that this inhibition is a
combined effect of doxycycline on the classic neutrophil and the newly discovered
“mesenchymal” collagenases of MMP-8 type. Finally, the anti-microbial and anti-
collagenolytic effects of tetracyclines can be dissociated at the molecular level: removal of
the dimethylamine group from the carbon number four from the A-ring of the tetracycline
(this structurally modified tetracycline is called CMT-1) abolishes its anti-microbial effects,
whereas the anti-collagenolytic effects remain. The IC50 values of neutrophil and fibroblast
collagenases for CMT-1 are 31 and 510 µM, respectively. The promising clinical results and
the underlying molecular effects encourage further developments in the field.
In the past years, the development of chemically modified tetracycline compounds has lead
to phase I and II clinical trials with compound CMT-300 (Kocer et al., 2005)
62
8.4 Discussion (IV)
Methodological aspects
The primary data of this cross sectional, retrospective study based on clinical records can be
considered reliable due to the extensive interview protocol used for educational purposes in
Finnish dental schools. The accuracy of the entries and the thoroughness of clinical
examinations are controlled by a senior staff member.
Our subjects are Finnish adult periodontitis patients from Helsinki area. The number of teeth
in our subjects coincides well with the reported mean number of teeth for a Finnish
population of this age group (NPHI 2004). The study subjects consisted of cardiovascular
risk patients receiving regular statin medication and controls without statin medication. In
Finland, statins can be prescribed only by licensed physicians for diagnosed need of primary
and secondary prevention of CVD.
Subjects in the statin group were on average older than controls. Clinical signs of
periodontal tissue destruction tend to increase with age (Albandar & Rams 2002). The
percentage of patients with diabetes was higher in the statin group than in the control group.
This is in accordance with the high risk of CVD in diabetes patients (Booth et al., 2006),
which results in their inevitable overrepresentation in subjects with statin medication. The
proportion of current smokers was higher in the statin group than in controls. Both diabetes
and smoking are predisposing factors for deterioration of periodontal tissue (Pihlström et al.,
2005), further emphasising the importance of our findings.
The inflammatory potential of dentition is proportional to the number of teeth. All of our
subjects had at least 15 remaining teeth, thus having at least 50% of the total possible dental
inflammation sites. There was a small difference in the number of teeth between the groups.
Although statistically significant, this difference did not affect the comparison between
statin and control groups. This indicates that statins have a substantial effect on local
periodontal inflammatory injury.
Periodontal inflammatory burden
Untreated periodontal pockets may serve as a source of persistent medium-grade
inflammation with systemic consequences. Moreover, deep periodontal pockets liberate
more inflammatory mediators and cytokines than shallow pockets, thus contributing more to
the inflammatory burden. We used PPD to describe periodontal inflammatory injury. The
number of tooth surfaces with increased PPD values reflects the total inflammatory burden
caused by the local periodontal inflammation. The use of PPD instead of loss of clinical
tooth attachment (PPD + gingival recession) is well reasoned in this context because
measurements of clinical attachment loss do not reflect the inflammatory area of soft tissues
surrounding the teeth.
63
The Periodontal Inflammatory Burden Index (PIBI) developed for this study takes into
account the enlargement of inflamed subgingival surface area in the deeper periodontal
pockets. This is achieved by representing the impact of deep periodontal pockets with a
coefficient. The actual value of the coefficient is probably greater than our estimate and
remains to be elucidated in future studies.
Inflammation and CVD
Inflammation and injury have long been thought to participate in the pathogenesis of
atherosclerosis (Lindy et al., 1972; Ross & Glomset 1976a; 1976b; Hansson 2005).
Considerable evidence supports the association between inflammation and vascular disease.
For example, in the WISE study, a clear correlation was found between serum inflammatory
markers and CVD events measured as death rates (Kip et al., 2005). Rheumatoid arthritis, a
major systemic inflammatory process, has been shown to be an independent risk factor of
CVD (del Rincón et al., 2001). Rheumatoid arthritis likely increases the risk of CVD
through the generalized increase of inflammatory mediators, probably by affecting the
endothelium of the arterial tree and promoting development of fatty streaks and eventual
atheroma (Roman et al., 2006). Even allergy and asthma, inflammatory diseases much more
common than rheumatoid arthritis, have been suspected to increase prevalence of CVD
(Schanen et al., 2005). The adverse effect of diabetes on CVD is probably partly
inflammatory in nature (Semenkovich 2006; Shoelson & Goldfine 2006). A decrease of
inflammatory substances in the blood has been suggested to be behind the favourable anti-
atherosclerotic impact of physical exercise on CVD (Hammett et al., 2006). An increase in
inflammatory markers in circulation has been found to mediate the adverse effects of obesity
on physical health (Semenkovich 2006; Shoelson & Goldfine 2006). All of these factors
have a common denominator, inflammation.
Periodontitis and CVD
Evidence suggests that periodontal inflammation has systemic effects and can be a burden
on remote tissues (Buhlin et al., 2003), although the inflammation is milder and more local
than in, for instance, rheumatoid arthritis. It is noteworthy that the prevalence of rheumatoid
arthritis in the general population is about 1%, whereas the prevalence of gingival
inflammation exceeds 50% (Albandar & Rams 2002). Chronic periodontitis causes
deterioration of the diabetic condition (Mealey 2006), and oral infections increase obstetric
complications (Offenbacher et al., 2006). Reduced number of teeth has been shown to be a
corollary of development of CVD (Paunio et al., 1993; Ajwani et al., 2003), and an
independent risk factor of aortic valve sclerosis (Völzke et al., 2005). The inflammatory
component may be an important link between periodontal diseases and development of CVD
(Pihlström et al., 2005; Deliargyris et al., 2004; D’Aiuto et al., 2004; 2006; Meurman et al.,
2004).
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Our results indicate that patients on statin medication exhibit fewer clinical signs of
periodontal inflammatory injury than subjects without the statin regimen. This may lead to
development of novel therapeutic approaches. Atorvastatin is a more potent cholesterol
lowering compund than simvastatin (Jones et al., 2003). Interestingly, in our study,
simvastatin and atorvastatin showed an equal association with low values of periodontal
inflammatory burden index PIBI. Our findings provide a new perspective to the published
literature, especially to studies on CVD that lack data on periodontal status. Data on oral
health should be included in epidemiological research on CVD.
8.5 GENERAL DISCUSSION
Strengths of Study I
In study I, we compared effector reserves of leukocytes in the peripheral blood and at site of
inflammation in a human study with simulataneous record of clinical parameters. This
approach had been tested and used by our group previously (Konttinen et al. 1990, 1991).
Weaknesses of Study I
One of the weaknesses of the methodological choices in sstudy I was use of synthetic
peptide substrates. The synthetic peptide substrates are not specific enough to allow stating
that the chymotrypsin-like activity would be exclusively from a specific cell type. Using
immunologic detection on same samples could ameliorate this problem. This technique, on
the other hand, does not definitely prove presence of active effector molecule but is merely
an observation of immunoreactivity at specified locations.
Reaction of the scientific community to Study I
During the 10 years following the publication of study I, 10 research groups have referred to
the Study I. Most of researchers just cited our results, and one group got consistent results
(Simard et al., 2006). On the other hand, a group studying a rat arthritis model got results
that could be interpreted such that PMN elastase would not play a role in rat carrageenan-
induced arthritis (Fujie et al., 1999). This could be either a species-related effect or a
phenomenon that is related to the specific animal model of arthritis.
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Strengths of Study II
In study II, we collaborated with another European research group to increase the
methodological repertoire available. By combining our efforts, we obtained results that in
separate laboratories would have required a longer period of methodological work. We
could report the immunoreactive and presence of collagenase-1 and collagenase-3 in human
rheumatoid synovial membrane samples.
Weaknesses of Study II
Limitations of the study are that the study is limited to functional assays and protein
detection. An additional palette of nucleic acid methods: mRNA detection, or using primary
cell cultures could have brought more information on the subject. At the time of the study,
however, it seemed aoppropriate to report the results to the scientific community.
Reaction of the scientific community to Study II
After the publication of Study II and similar reports by several research groups (Wernicke et
al., 1996; Ståhle-Bäckdahl et al., 1997), it has been accepted that MMP-13 is present in the
rheumatoid synovial tissue. During the subsequent years, especially Kähäri and coworkers
have elucidated the role of MMP-13 and the regulation of its expression (Westermarck &
Kähäri 1999, Kähäri & Saarialho-Kere 1999).
Strengths of Study III
The strengths and positive ascpects in the design of study III are the prospective (though
open-label) nature, and multidisciplinary observation of patient outcome in addition to
biochemical effector molecules.
Weaknesses of Study III
Limitations of study III are obvious: the number of patients used in this type of study
performed in a single clinic do give justification to limited reasoning only. Due to this fact,
we tried to use as wide variety of methods as possible, available to us at the time.
Reaction of the scientific community to Study III
Yrjänheikki et al. reported in results that indicated possible neuroprotective action of
doxycycline (Yrjänheikki et al., 1998). In 1999, O’Dell et al. published their results of a
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prospective double-blind study on minocycline in 20 patients with rheumatoid arthritis
(O’Dell et al., 1999), where they showed a lower need for disease-modifying antirheumatic
drugs in patients on minocycline during a four-year follow-up.
Strengths of Study IV
The strengths of study IV were in combining knowledge of recent results from the field of
internal medicine, the existing statistical reports on purchase of prescription drugs in
Finland, the systematic approach to patient status in the University Dental Clinic, and
careful planning of study design.
Weaknesses of Study IV
In spite of the above, study IV is a cross-sectional cohort study, so we are limited to
describing the observations we made. On the other hand, we could carried out the study with
no external monetary funding, and restrained the study size to that predicted by
precalculations. An obvious limit, though, remains that without biochemical data on cellular
responses or prospective studies on human subjects, we have not proved any specific
mechanism to be involved, presenting arguments regarding the mechanisms involved are
restrained to suggestions in the discussion of the study.
The central theme common to all studies I-IV is chronic inflammation in human disease
models. Through these studies, we could contribute to the scientific body of knowledge on
some aspects of inflammation. Still, this is only a beginning and a lot of questions remain to
be solved in future studies.
SUMMARY & CONCLUSIONS
Has been moved to the beginning as stated in the instructions of the faculty.
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